Dr. Herman Weiss

The Pause Collective Science Review, Issue 11: October 13-16, 2026

Dr. Herman Weiss — Fri, 16 Oct 2026 14:20:12 GMT

Dr. Herman Weiss

Oct 16, 2026

Welcome back to The Pause Collective Science Review, where I read the science so you don't have to. Most days the literature is a slow drip. This was not one of those weeks: America's ob-gyn college published its most comprehensive menopause guidance to date, and the PMOS literature delivered two papers that speak directly to where those women are heading in midlife. Five papers, annotated and referenced, plus what is trending.

1. ACOG finally weighs in, properly: a full guideline for hot flashes, sleep, and mood

Two weeks ago in Issue 8 we reviewed the American College of Physicians' new guideline on vasomotor symptoms. Now the American College of Obstetricians and Gynecologists has published Clinical Practice Guideline No. 13 - its most complete menopause guidance to date - covering vasomotor symptoms (hot flashes and night sweats), sleep disruption, and mood changes, in both spontaneous and induced menopause.

What it says: hormone therapy is an important tool, and starting it should be a shared decision based on symptoms, age, medical history, and baseline cardiovascular, breast cancer, and clotting risk. If chosen, ACOG recommends starting before age 60 or within 10 years of menopause in women without contraindications - the timing hypothesis I have written about here more than once. For women who cannot or prefer not to use hormones, the guideline reviews nonhormonal medications, including the neurokinin receptor antagonists fezolinetant and elinzanetant, plus SSRIs and SNRIs that can serve both hot flashes and depression. Non-drug options - cognitive behavioral therapy, mindfulness-based approaches, exercise, clinical hypnosis, acupuncture - get evidence-based recommendations too, usually as complements. It also calls for earlier patient education, and a companion guideline on genitourinary syndrome is promised for 2027.

The context behind it is sobering: 50-92% of women report vasomotor symptoms, 16-66% report menopause-related sleep disruption, and more than a third report depressive symptoms. ACOG's president framed the release explicitly against menopause misinformation.

My take: this matters less for any single recommendation - most mirror what the Menopause Society already says - and more for who is saying it. ACOG is the home institution of the generalists who see the most women, and it is pairing the guideline with a full menopause special issue of its journal. Guidelines do not change practice overnight, but they change what insurance covers and what clinicians feel permitted to offer. The limits: this is a guideline, not new data, and its recommendations are only as strong as the underlying trials, several of which (acupuncture, hypnosis) rest on modest evidence.

Citation: American College of Obstetricians and Gynecologists. Clinical Practice Guideline No. 13: Management of Menopause-Related Vasomotor, Sleep, and Mood Symptoms. Obstet Gynecol, 2026 (November issue; published October 15). doi:10.1097/AOG.0000000000006428.

2. Menopause before 40 nudges diabetes risk up - and hormones change the picture

The Women's Health Initiative keeps giving. Researchers followed 136,759 postmenopausal women aged 50-70 and asked whether premature menopause (before age 40, experienced by 9.7% of the cohort) predicts type 2 diabetes later.

What they found: a modest but real signal. Women with premature menopause had about a 10% higher relative risk of developing diabetes (hazard ratio 1.10, 95% CI 1.05-1.16) compared with women reaching menopause at 50-54. The detail I find most interesting: hormone therapy modified the risk. Among women with natural premature menopause, the elevated risk appeared in those who never used hormone therapy (HR 1.24) and those who used estrogen-plus-progestogen (HR 1.35), but not in estrogen-only users. And BMI explained roughly 28% of the association - body weight is a meaningful part of the mechanism, not the whole story.

In plain English: losing ovarian function early costs you some metabolic protection, and the hormone story is not simple - estrogen alone looked neutral here, while the combination did not. Limits: menopause timing was self-reported, diabetes was defined by treatment initiation, and this is observational - no causation claims. For my PMOS readers: your risk story runs the opposite direction in one sense (many of you will reach menopause later), but the shared lesson is that ovarian hormones and metabolic health are entangled for decades, and weight management is leverage you actually hold.

Citation: Du Y, LeBlanc ES, Shadyab AH, Liu L, Banack HR, Wild RA, Saquib N, Spracklen CN. Premature menopause and risk of type 2 diabetes among postmenopausal women: findings from the Women's Health Initiative. Menopause, 2026 (published October 13). doi:10.1097/GME.0000000000002907.

3. Depression before menopause flags heart risk after it

A large real-world study using the TriNetX network matched 88,884 postmenopausal women who had been diagnosed with depression before menopause against 88,884 similar women who had not - excluding anyone with existing cardiovascular disease or conventional risk factors like smoking, diabetes, hypertension, or obesity.

What they found: over up to 20 years of follow-up, 4.0% of the premenopausal-depression group developed cardiovascular disease versus 3.3% of controls - a relative risk of 1.23 (95% CI 1.17-1.29). The absolute difference is small, about 7 extra cases per 1,000 women, but the cohort is enormous and the matching careful.

In plain English: depression in your 30s and 40s is not only a mental-health diagnosis - it is a midlife cardiovascular risk marker worth writing on your chart, the way we already treat family history. It does not mean depression causes heart disease; the study cannot say that. But it means a woman with that history deserves earlier, more deliberate cardiovascular prevention conversations. For PMOS readers: depression and anxiety rates run high in PMOS, so this cohort finding is doubly relevant - mood care is heart care, starting long before menopause. Limits: retrospective, database-based, and the proportional-hazards assumption failed, so treat the hazard ratio as an average, not a constant risk.

Citation: Raju P, Jiang LF, Kutty A, Nudy M. Premenopausal depression and risk of cardiovascular disease after menopause: a large real-world cohort study. Cardiology, 2026 (published October 15). doi:10.1159/crd/absag025.

4. A liver drug finally tested in the women who need it: saroglitazar in PMOS with fatty liver

Here is a gap I have complained about before: women with PMOS have high rates of fatty liver disease (MASLD), yet they are systematically underrepresented in liver drug trials. This multicenter, double-blind, placebo-controlled phase 2A trial randomized 60 women aged 18-45 with PMOS and MASLD to saroglitazar 4 mg (a dual PPAR-alpha/gamma agonist) or placebo for 24 weeks.

What they found: liver fat (measured by MRI-PDFF, the proper way) fell about 15% relative to baseline in the treatment group versus a slight rise on placebo (p=0.041); adjusted for a baseline HbA1c imbalance, the gap widened. More than a third of treated women (36%) achieved at least a 30% liver-fat reduction versus 8.7% on placebo, and liver enzymes, lipids, and fibrosis-risk scores improved too. Side effects were comparable between groups, none serious.

In plain English: this is early-phase and small, but it is the right drug class (metabolic, insulin-sensitizing) tested in the right population for once. Saroglitazar is already used in India for diabetic dyslipidemia; this trial makes a case for a dedicated PMOS-liver indication. And for readers heading toward perimenopause with a PMOS history: liver fat tends to rise in the menopause transition, so having therapies tested in your phenotype matters for the decades ahead. Limits: 60 women, 24 weeks, per-protocol analysis - promising, not practice-changing yet.

Citation: Samala N, Gonzalez-Gonzalez J, Jenders R, Sarkar M, Reza R, Rodas F, Kipnes M, Gonzalez EM. Saroglitazar improves hepatic steatosis and liver enzymes in women with polycystic ovary syndrome and MASLD: a multicenter, double-blind, placebo-controlled study. Hepatology, 2026 (published October 15). doi:10.1097/HEP.0000000000001862. Trial NCT03617263.

5. PMOS and the aging brain: what we actually know about the Alzheimer's link

You may have seen headlines this week linking PMOS to dementia (the Endocrine Society issued a press release, and Newsweek ran the story). The source is this new comprehensive review in the Journal of the Endocrine Society, led by Ricardo Azziz's group - the same team behind the PMOS renaming effort - surveying everything published through October 2025 on cognition, brain imaging, biomarkers, and dementia risk in PMOS.

What it found: plausible mechanisms exist (insulin resistance, chronic inflammation, hormonal dysregulation, cardiovascular dysfunction, all converging on amyloid and tau biology), and women with PMOS show mild but reproducible deficits in executive function and memory plus subtle imaging changes. But - and this is the part the headlines underplay - direct epidemiological evidence that PMOS independently raises dementia incidence is limited and inconsistent. The association, where it exists, appears largely mediated by metabolic comorbidities, particularly insulin resistance and obesity, not by PMOS itself. No PMOS-specific intervention has yet shown cognitive benefit.

In plain English: the honest summary is "reason to manage your metabolism, not reason to panic." This is exactly the cross-education point I make to both audiences: the same insulin-resistance-and-inflammation machinery that drives midlife cardiovascular risk in PMOS is what we watch in brain aging after menopause. Manage the metabolism and you are already doing the brain-protection work. Limits: this is a narrative review of heterogeneous studies, not new data.

Citation: Amiri M, Kakavand Hamidi A, Farkas DL, Buyalos RP, Azziz R. Potential links between PCOS/PMOS and Alzheimer disease and related dementias. J Endocr Soc, 2026 (November issue; press coverage October 13-14). doi:10.1210/jendso/bvag206.

Cross-references (covered elsewhere, one line each): the ACP vasomotor-symptom guideline was fully reviewed in Issue 8 (October 7). The metformin-before-IVF cohort got Post #10 (October 7), and this week's Journal of Gynecology paper on metformin plus myo-inositol for fertility in PMOS sits close enough to it that I am noting rather than re-reviewing it. The soy/isoflavone umbrella review for cholesterol after menopause became this week's single-study post (#12, published today).

WHAT'S TRENDING

Grounded in coverage I could actually read this week (news outlets and society press releases); I did not browse TikTok or Reddit directly this cycle, so platform-specific sentiment below is inference from what is getting amplified, and I say so.

The ACOG guideline dominated the professional feed within hours (ACOG newsroom, Healio, Contemporary OB/GYN, Endocrinology Advisor, October 15). Expect it to be the talk of the Menopause Society Annual Meeting, which opens October 20 in San Diego. Watch for the usual distortion: "ACOG says every woman should take hormones." It does not say that - it says individualized, shared decisions, before 60 or within 10 years.
UK HRT shortage warnings resurfaced (BBC, October 14) - a new geography on a story we tracked in Spain and Europe in Issue 9. Shortages push women toward unregulated substitutes; if your product is unavailable, the answer is a pharmacist-supervised switch, not a marketplace.
Testosterone-for-menopause skepticism got a well-reported expert piece (Live Science, October 15: "No one studied the safety"). This matches what I wrote in Post #8 - the cognition evidence is thin and the marketing is ahead of the data. The pendulum of the conversation is swinging from hype toward scrutiny, which is healthy.
PMOS had a mainstream media week: the Alzheimer's-link review above was amplified by the Endocrine Society (October 13) and Newsweek (October 14), and ABC News ran a "PCOS gets a new name" explainer (October 14) - the rename story reaching general-audience US television coverage is new. My read: the name is now in the adoption phase we tracked in Issues 8 and 9.
In supplement marketing, a postbiotic Akkermansia product is being promoted to the PMOS community with metabolic and endocrine claims (trade press, this week). The underlying science on Akkermansia is genuinely interesting and genuinely early - mouse-to-human translation is where good intentions go to die. No PMOS-specific trials behind the marketing that I could find.

Until the next one,

Dr. Herman Weiss

Medical Disclaimer

The information provided in this blog post and newsletter is for educational and informational purposes only. It does not constitute medical advice or professional services and should not be used to diagnose or treat any health problem or disease. Always seek the advice of your physician or other qualified health-care provider regarding a medical condition. Never disregard professional medical advice or delay seeking it because of something you have read here. Use of this content does not create a doctor-patient relationship. Individual responses to treatments and lifestyle changes can vary, and only your healthcare provider can evaluate your specific circumstances. If you are experiencing a medical emergency, call your local emergency services immediately.

Soy After Menopause: What the Entire Evidence Stack Says About Your Cholesterol

Dr. Herman Weiss — Fri, 16 Oct 2026 06:05:23 GMT

Photo by Andreas Rasmussen on Unsplash

Dr. Herman Weiss
Oct 16, 2026

Few foods carry as much menopause baggage as soy. It has been marketed as nature's hormone therapy, dismissed as hype, and feared - unfairly - as an estrogen risk. This week, instead of one more small trial, researchers did something more useful: they gathered every meta-analysis of randomized trials on soy and cholesterol in postmenopausal women, and graded the whole stack. An umbrella review - a review of reviews.

The research: Guo and colleagues searched PubMed, Web of Science, Embase, and Cochrane through April 2026 and found seven meta-analyses covering 21 separate outcome associations. They rated each review's methodology (AMSTAR-2) and the certainty of each finding (GRADE) - the two standard scorecards for this kind of work.

The findings, in plain numbers. Soy protein containing isoflavones, and soy isoflavone extracts, reduced total cholesterol by about 0.12 mmol/L (roughly 4-5 mg/dL). Isoflavones reduced LDL cholesterol by a small standardized margin. Unfermented soy foods - tofu, soy milk, edamame - raised HDL cholesterol by about 0.06 mmol/L (around 2 mg/dL). No convincing effect on triglycerides. The trials behind these numbers used isoflavone doses of 40-165 mg a day, over 12 to 144 weeks.

Two honesty notes from the reviewers themselves. Only two of the seven meta-analyses were rated moderate or high quality - the rest had methodological cracks. Still, 18 of the 21 associations were supported by moderate- or high-certainty evidence, so the direction of the finding is stable even where the individual reviews wobbled.

What you gain from this: first, permission to stop expecting miracles. These are real effects, but they are small - a few points off total cholesterol, a couple onto HDL. Soy is not a statin, and nobody should swap one for the other. Second, precision: the benefits attached to SPECIFIC products - soy protein with its isoflavones intact, isoflavone extracts, and traditional unfermented soy foods - not to "soy" as a vague health halo, and certainly not to every soy-branded snack on the shelf. Third, a realistic frame: if you enjoy tofu, soy milk, or edamame, include them freely as part of a heart-conscious pattern - they nudge your lipids in the right direction while contributing protein, which midlife women need more of anyway. A food that helps a little, tastes good, and costs nothing extra in risk is an easy yes.

For my PMOS readers: this review covered postmenopausal women, not PMOS - the soy-and-PMOS literature is separate and thinner, so do not import these numbers. But the underlying lesson transfers perfectly: judge interventions by specific products and measured effect sizes, not by category hype.

The caveats: umbrella reviews inherit every weakness of the trials beneath them, and most of the component reviews here were low quality. The effect sizes are small enough that your baseline cholesterol, your overall diet, and what the soy REPLACES on your plate matter more than the soy itself. And this review studied lipids, not hot flashes or bone density - claims about soy for symptoms are a different evidence file entirely. If you have an estrogen-sensitive condition or a history of breast cancer, phytoestrogen supplements (as opposed to ordinary soy foods) remain a conversation for your doctor, not a default.

The bottom line: soy's reputation has swung between superfood and scare story for thirty years. The best current synthesis says it is neither - it is a modest, genuine, cholesterol-friendly food. In midlife nutrition, modest and genuine is underrated.

Until the next one,

Dr. Herman Weiss

Medical Disclaimer

Resistance Training Helps the Midlife Brain - and the Stage of Menopause Changes How

Dr. Herman Weiss — Thu, 15 Oct 2026 06:35:09 GMT

Photo by Limor Zellermayer on Unsplash

Dr. Herman Weiss
Oct 15, 2026

Here is a number I think about often: two-thirds of people with dementia are women, and women carry roughly twice the lifetime risk. Researchers have suspected for years that perimenopause - the stormy hormonal transition of the mid-to-late forties - is one reason why. The obvious follow-up question: can exercise during that window protect the brain? Until now, no randomized trial had tested resistance training (weights, machines, bands) on cognition across the stages of menopause. The first one just landed.

The research. The SMART brain study (BMC Medicine, September 30) is a pilot sub-study of an assessor-blinded randomized trial from the University of Calgary. Forty women aged 45 to 60 - some in perimenopause, some in early postmenopause - were randomized to nine months of supervised, progressive resistance training twice a week, or to a wait-list control. Thirty-five of them (17 training, 18 control) volunteered for the brain sub-study, which measured cognition with the NIH Toolbox battery and brain blood-flow responses with functional near-infrared spectroscopy (fNIRS) - a light-based way of watching the prefrontal cortex work during a task.

What they found. The interesting result is not just that training helped - it is WHERE it helped, and when. Memory improved with training in the women who were still in perimenopause. Set-shifting - the mental flexibility to switch between tasks - improved with training in the women who were already past menopause. And the blood-flow response in the left dorsolateral prefrontal cortex (a hub for attention and working memory) increased with training only in the postmenopause group. In other words: the same exercise, two different reproductive stages, two different cognitive wins. The brain's window of responsiveness seems to move as hormones shift.

What you gain from this. If you are in your forties or fifties and keep forgetting why you walked into a room, this is one more concrete reason to pick up weights twice a week - not for your jeans, for your neurons. The intervention was realistic: supervised sessions, twice weekly, progressive. And the stage-specific finding is quietly hopeful: it suggests there is no single "too late" point. Perimenopause and early postmenopause each responded - just differently.

For my PMOS readers: this study was not about PMOS, and I am reading across, not quoting it. But many of you have lived with insulin resistance for decades, and muscle is your biggest glucose sink. If resistance training helps the midlife brain AND improves the metabolic terrain you already manage, that is two wins from the same habit. When you reach the perimenopause window, you will want this tool already in your routine.

Now the honest limits. This is a pilot: 35 women, one center, nine months. The statistically solid findings are the stage-by-group interactions, not a blanket "weights boost memory" claim. The control group waited rather than doing a sham exercise, so expectation effects are possible. fNIRS watches cortical blood flow, not deep brain structure, and blood flow is a proxy, not proof of protection against dementia. And nine months cannot tell us whether the benefit lasts or prevents anything decades later. The authors say the same: this is the case for a bigger trial, not a finished answer.

I still find it one of the more useful papers this year, because it turns "exercise is good for you" into something more precise: the midlife female brain is trainable, and its respond-to-exercise settings change across the menopause transition. Start where you are.

Dr. Herman Weiss

Medical Disclaimer

The Pause Collective Science Review, Issue 10: October 9-13

Dr. Herman Weiss — Wed, 14 Oct 2026 06:46:30 GMT

Photo by Spenser Sembrat on Unsplash

Dr. Herman Weiss
Oct 14, 2026

Welcome back to The Pause Collective Science Review - the twice-a-week edition where I read the new menopause and PMOS research so you don't have to. This cycle's lead paper is one of the biggest menopause studies I have ever seen, and it comes with a built-in scientific argument I want you to hear both sides of. Three more papers round out a practical theme: what actually changes, and what actually helps.

1. Menopause is a cliff, not a slope - 300 million lab tests redraw the transition

A team led by Uri Alon at the Weizmann Institute (with Clalit Health Services) asked a deceptively hard question: when exactly does the body change at menopause? Longitudinal cohorts like SWAN say "gradually, over years" - but those studies are small. The problem with big datasets is that nobody records the date of a woman's final menstrual period, so every woman's timeline blurs into everyone else's. Their fix is a computational method borrowed from astronomy that un-blurs the data, anchoring every lab result to each woman's own final period. Applied to two independent cohorts - the US NHANES survey and Israel's Clalit - totaling more than 300 million lab tests from over a million women between 1999 and 2024.

The finding: at the final menstrual period, the body does not glide - it steps. Nearly every physiological system they measured showed an abrupt, jump-like shift: sex hormones (no surprise), but also bone metabolism, liver function, kidney function, lipids, and blood counts. Men show no such jumps at the same ages, so this is menopause, not generic aging. The two cohorts - American and Israeli - agreed with each other. Two more results matter to us. First, the dysregulation starts early: the drift begins more than a decade before the final period. Second, women on menopausal hormone therapy showed markedly smaller jumps - the bigger the jump, the larger the correction with MHT. And the clinical echoes: osteoporosis prevalence steepens right at the final period, and cardiovascular events accelerate after it.

What this means for you: if you have ever felt that your body changed "all at once" around menopause and been told it's just gradual aging - this study says your perception has data behind it. It also reframes prevention: if the drift starts ten-plus years out, then perimenopause is not "too early" to act - it is exactly when the acting happens. For my PMOS readers: your baseline hormonal pattern is already atypical, and we know from last issue's genetics update that the same gene regions help set both PMOS biology and menopause timing. How this cliff looks in PMOS is an open question I would love to see this team answer next. And a note of local pride: half of this dataset is Israel's own Clalit.

The limits, and the argument: the final menstrual period here is inferred by a model, not recorded; this is a clever reconstruction of cross-sectional data, not a follow-women-for-decades cohort. Lab values are not symptoms or diagnoses. And the MHT comparison is observational - women who take hormone therapy differ from women who don't. The debate is already live: Martha Hickey, head of menopause services at the Royal Women's Hospital in Melbourne, told ABC the "cliff" framing is "unnecessarily alarming" and not a medical term. My read: both things are true. The underlying drift is real and starts early (the gradualists' point), AND there is a genuine step at the final period that age-based averages have been hiding (the authors' point). Neither is a reason to panic; both are reasons to plan.

(Pridham G, Hayut Y, Lavi-Shoseyov N, Neeman M, Hovav N, Toledano Y, et al., Alon U. Population-scale reconstruction of menopause dynamics reveals a physiological cliff at the final menstrual period. Nat Med, 2026. doi:10.1038/s41591-026-04614-0)

2. Tai Chi for the menopause brain: a small trial with an unusually deep look

A randomized trial from Fuzhou, China took 40 postmenopausal women with mild cognitive impairment (MCI) and assigned them to 12 weeks of supervised 24-form Tai Chi or a health-education control group. What makes this exploratory trial worth your attention is everything they measured around the exercise: not just cognitive scores, but brain blood flow, vessel-function markers, and circulating Alzheimer's-related proteins.

The Tai Chi group's MoCA scores improved about 5 points more than the control group's (a clinically meaningful gap), with the biggest gains in delayed recall, visuospatial/executive function, and attention. Cerebral blood flow rose globally and in cognition-related regions. The bloodwork moved in the right direction too: nitric oxide (a vessel-relaxing signal) up, the vasoconstrictor-to-NO ratio down, and circulating T-tau, P-tau, and amyloid-beta 1-42 - proteins linked to Alzheimer's pathology - all significantly lower than control. No intervention-related adverse events.

What this means for you: I am not going to tell you Tai Chi prevents dementia - a 12-week exploratory trial cannot say that. But if you are a postmenopausal woman noticing your memory is not what it was, this is one more honest data point that structured, regular movement is the best-supported non-drug lever we have for the menopause brain, and Tai Chi is a low-impact, joint-friendly, genuinely pleasant way to pull that lever. The perfusion finding is the interesting part: it suggests the benefit is partly vascular - better blood flow, not just practice effects.

The limits: 40 women, one center, open-label (participants knew their group), 12 weeks, explicitly exploratory. Blood biomarkers of Alzheimer's are proxies, not outcomes; whether any of this touches actual dementia rates is unknown. Consider this a strong rationale for the bigger trial, and a reasonable nudge to start moving now.

(Zheng Y, Hong L, Wu L, Chen X, Hu Q, Chen L, Ni X, Zhuang X, Yin L. Effects of 12-week 24-form Tai Chi on cognitive function, cerebral perfusion, and vascular function in postmenopausal women with mild cognitive impairment: an exploratory randomized controlled trial. Front Aging Neurosci, 2026. doi:10.3389/fnagi.2026.1880915)

3. PMOS bone density looks better - but the strength does not follow

Here is a study that overturns an assumption. We have long thought PMOS might be somewhat protective for bones (higher androgens, higher average weight - both load the skeleton). A cross-sectional study used high-resolution peripheral quantitative CT - a scanner that sees bone microarchitecture, not just density - in 23 obese women with PMOS, 21 BMI-matched obese women without PMOS, and 24 normal-weight controls. Matching by BMI is the key design choice: it separates PMOS itself from the weight it often travels with.

The PMOS group did show higher volumetric bone density at both the radius and tibia, including denser cortical bone - so the assumption survives the density test. But here is the twist: estimated bone strength (stiffness and failure load, computed from the scans) was NO better than the BMI-matched controls. Density up, strength flat. And testosterone - the obvious suspect for explaining the difference - mediated nothing.

What this means for you: if you have PMOS, do not let a reassuring bone-density number talk you out of bone care. Density is quantity; strength is quality, and this study says the two can come apart. For my menopause readers, this is the mirror-image lesson of the week: the cliff paper shows bone metabolism jumping at the final period, and this one warns that a good baseline number is not armor. The boring levers - resistance training, protein, vitamin D adequacy, not smoking - work on the strength side of the equation. Women with PMOS heading into perimenopause: you need them as much as anyone.

The limits: small groups, cross-sectional (one snapshot, no fractures tracked), obese populations only at the PMOS end, and estimated strength from finite-element modeling rather than real-world fracture outcomes. The answer on actual fracture risk in PMOS needs a long longitudinal study we do not have yet.

(Zhao Y, Zhang Q, Gong F, Duan L, Zhang Y, Wang L, Zhu H, Xia W. Bone microarchitecture and strength in obese women with and without polycystic ovary syndrome (PCOS): a peripheral quantitative computed tomography (pQCT) study. Front Endocrinol (Lausanne), 2026. doi:10.3389/fendo.2026.1935187)

4. AMH tells you about the ovaries, not the metabolism - 1,147 women settle it

Anti-Mullerian hormone (AMH) is everywhere in PMOS care - it is part of how the condition is diagnosed and how ovarian reserve is gauged. A natural clinical question: since PMOS is so entangled with weight and metabolic dysfunction, does a woman's AMH also say something about her adiposity or metabolic risk? A Polish team measured AMH alongside detailed body composition (including visceral fat area by bioimpedance) and metabolic panels in 1,147 women newly diagnosed with PMOS.

The answer is clean: no. AMH's correlations with every adiposity marker - waist-to-hip ratio, visceral fat area, lipid accumulation product, cardiometabolic index - were negligible (correlation coefficients around 0.05-0.1, statistical noise dressed as significance thanks to the huge sample). Meanwhile the metabolic markers themselves were tightly interlocked exactly as expected (visceral-fat indices tracked fasting insulin and insulin resistance at r around 0.67-0.76). When they ran a principal-component analysis, the metabolic dimensions explained 68.8% of the variance - and AMH correlated with none of them.

What this means for you: two women with PMOS can have identical AMH levels and completely different metabolic risk profiles. AMH is a reproductive signal, not a metabolic one - it should be read against your age and reproductive picture, and it cannot substitute for actually measuring insulin, lipids, and waist circumference. If your AMH is "good," that says nothing about your metabolic risk; if it is high (as PMOS often makes it), that says nothing protective either. For my menopause readers: AMH is also the number marketed to you as a "menopause countdown clock" - same lesson, different stage. It reflects the ovaries' bookkeeping, and it was never a whole-body health score.

The limits: cross-sectional, bioimpedance rather than imaging for visceral fat, and a single-ethnicity cohort. The correlations were so weak, though, that the core message - AMH is not a metabolic marker - is unlikely to flip.

(Kowalczyk K, Galczynska D, Herman J, Czyz M, Kowalczyk D, Drosdzol-Cop A, Franik G. Anti-Mullerian hormone in relation to adiposity and metabolic indices in polyendocrine metabolic ovarian syndrome. Front Endocrinol (Lausanne), 2026. doi:10.3389/fendo.2026.1975667)

What is trending

The Nature Medicine "cliff" paper is the menopause story of the week, and the argument about it is healthy. Coverage ranges from breathless ("Bones, Liver, And Blood Fats All Shift Abruptly at Menopause" - ScienceAlert) to openly skeptical (ABC's piece quoting Australian specialists who call the framing alarmist). My annotation above is the middle path. If your feed shows you the scary version, remember: the same dataset shows hormone therapy markedly softens the jumps - the cliff is real, and it is also modifiable.

The Menopause Society's Annual Meeting opens October 20 in San Diego, and the pre-meeting press releases keep coming. The one getting traction this week: a Mayo Clinic retrospective cohort (about 2,400 women on semaglutide, 1,500 on tirzepatide) finding women on hormone therapy lost significantly more weight on semaglutide - with no significant interaction for tirzepatide. The Society's own caveats are correct: observational, retrospective, needs prospective confirmation, and weight loss is not an indication for MHT. Also queued for the meeting: a study linking combined estrogen-plus-testosterone therapy to lumbar spine bone density gains, and AbCellera's first phase 1/2 data on ABCL635, a non-hormonal drug candidate for hot flashes. Expect a full meeting-news cycle over the next two weeks; I will sort signal from noise as it lands.

On the PMOS side, the policy conversation is catching up with the science. Australia's PMOS association (POSAA) is publicly pressing for GLP-1 weight-loss drugs to be subsidized for PMOS on the national Pharmaceutical Benefits Scheme - currently they are prescribed off-label and cost patients hundreds of dollars a month (The Guardian, Oct 9). The Royal Australasian College of Physicians has not taken a position. Watch this space: if PMOS becomes a reimbursed indication anywhere, it will set the template everywhere.

A transparency note, as always: the above is grounded in news coverage and press releases I could read directly. I did not directly browse TikTok or Reddit threads this cycle, so I am not claiming to represent what those feeds showed today.

One cross-reference: Issue 9, published Sunday, covered the new PMOS gene map - 120 regions, several of which also help set menopause timing. It pairs naturally with this week's cliff paper.

Until the next one,

Dr. Herman Weiss

Medical Disclaimer

The Pause Collective Science Review, Issue 9: October 6-9

Dr. Herman Weiss — Sun, 11 Oct 2026 06:31:48 GMT

Photo by Patty Brito on Unsplash

Dr. Herman Weiss
Oct 11, 2026

Welcome back to The Pause Collective Science Review - the twice-a-week edition where I read the new menopause and PMOS research so you don't have to. Four papers this cycle, and a theme I did not plan but could not ignore: the body's history leaves clues, and medicine is finally learning to read them.

1. Irregular periods in midlife are a heart-risk signal - and the reason matters

Researchers asked a deceptively simple question: if a woman's periods are irregular in mid-adulthood, does it matter WHY? Using the Nurses' Health Study II cohort - 52,655 premenopausal women followed for up to 26 years, with 1,007 cardiovascular events along the way - they separated functional hypothalamic amenorrhea (FHA: irregular or absent periods without PMOS traits, typically paired with low body weight or heavy exercise) from other causes of irregular cycles.

The finding: women with the FHA pattern in mid-adulthood had a 62% higher risk of cardiovascular disease (hazard ratio 1.62, confidence interval 1.01-2.59), driven by nearly double the risk of coronary heart disease (HR 1.91). They also had an 86% higher risk of type 2 diabetes. Women whose cycles were irregular for OTHER reasons (including PMOS-like traits) had more cholesterol, blood pressure, and diabetes trouble - but not more heart attacks or strokes. And FHA in early adulthood, before about age 35, did not predict later events.

What this means for you: your menstrual history is not just a fertility story - it is a vital sign. If your periods were irregular or absent in your late 30s and 40s, especially alongside low weight or intense training, that is worth mentioning to your doctor the same way you would mention a family history of heart disease. For my PMOS readers: this study deliberately separated PMOS-type irregularity from FHA, and the risk profiles came out different. PMOS-type irregular cycles pointed at metabolic risk - cholesterol, blood pressure, blood sugar - which is exactly the terrain we already watch. Know which pattern is yours, because the follow-up differs.

The limits: this is an observational cohort of (mostly white) US nurses, the FHA group was small (that confidence interval nearly touches 1), and the phenotype came from questionnaires, not hormone panels. Association, not proof - but a well-done association in a very long-running cohort.

(Shufelt CL, Stuart JJ, Karam J, et al. Functional Hypothalamic Amenorrhea Phenotype and Cardiovascular Disease Risk. J Clin Endocrinol Metab, 2026. doi:10.1210/clinem/dgag405)

2. The PMOS gene map keeps growing - and it points at menopause too

Parker and Urbanek published a 2026 update on the genetic architecture of PMOS in Fertility and Sterility. Pooling 17 genome-wide association studies, researchers have now identified 120 genomic regions significantly associated with PMOS. Thirty-eight of them replicate in at least two independent cohorts, and most of those replicated regions hold up across multiple ancestries.

What are those genes doing? The list reads like a tour of everything we talk about here: gonadotropin secretion and action, follicle development, sex hormone function, adiposity, insulin signaling, type 2 diabetes, lipid and cholesterol levels - and, notably, age at menopause.

What this means for you: PMOS is not one disease, and genetics now proves it at scale. Different women arrive at the diagnosis through different biological doors, which is why one-size-fits-all advice keeps failing. For this community specifically: the same genetic regions implicated in PMOS also help set the timing of menopause. The biology of these two life stages is entangled - one more reason I cover them together. Today this changes no prescription; there is no clinical genetic test for PMOS. But this is how future subtypes and targeted treatments get built.

The limits: GWAS finds associations, not destiny - most of these regions each nudge risk only slightly, and the underlying data still skew toward European ancestries even though replication looks broader.

(Parker C, Urbanek M. Current Understanding of Genetic Architecture of Polyendocrine Metabolic Ovarian Syndrome (PMOS) - 2026 Update. Fertil Steril, 2026. doi:10.1016/j.fertnstert.2026.09.013)

3. Keto for PMOS: a small trial with big numbers

A single-center randomized trial in Frontiers in Nutrition put 60 women with PMOS (PCOS) on either a ketogenic diet (30 women: 70-75% fat, under 50 g of carbs a day) or a Mediterranean-style diet (30 women), same calories, a 500-kcal daily deficit, for 12 weeks. Ketosis was verified with blood and urine testing, so this was real keto, not wishful keto.

The results were striking. Menstrual regularity was restored in 96.7% of the keto group versus 66.7% of the Mediterranean group - a number needed to treat of about 3. The keto group lost far more weight (16 kg versus 6 kg), waist circumference (17 cm versus 6 cm), and visceral fat, with better fasting insulin, insulin resistance (HOMA-IR), and triglycerides. Both diets were safe over 12 weeks, with no serious adverse events and everyone completing the trial. The authors themselves suggest a sequential strategy: keto as a short metabolic reset, then transition to a Mediterranean pattern for the long haul.

What this means for you: if you have PMOS and struggle with insulin resistance, a supervised ketogenic phase is a legitimate thing to discuss with your doctor or dietitian - the trial used monitoring you should have too. And note that the Mediterranean arm was no slouch: two-thirds of those women also restored regular cycles. Food is medicine here either way; the question is intensity and sequencing.

The limits, and they matter: 60 women, one center, 12 weeks, open-label, and explicitly exploratory. We do not know what happens at month 13, or to fertility outcomes, or outside this population. Big numbers in a small trial are a reason for a bigger trial, not a reason to crown a winner.

(Wang M, Xie L, Ma L, Zhang C. Efficacy of ketogenic diet on glycemic-lipid metabolism and menstrual regularity in women with polycystic ovary syndrome: a randomized controlled trial. Front Nutr, 2026. doi:10.3389/fnut.2026.1920489)

4. Where fat sits shapes menopause symptoms - and estradiol is the middleman

A cross-sectional study from Shanghai (Frontiers in Endocrinology) measured 600 women aged 40-60, staged by STRAW+10 criteria, and asked how body composition relates to menopause symptom burden (Kupperman Index). Waist-to-hip ratio - where the fat sits - was independently associated with worse symptoms. Overall body fat percentage showed a weaker association. The clever part: mediation analysis suggested estradiol explains about 17.8% of the waist-to-hip-symptom link, while it mediated nothing for total body fat.

What this means for you: central, abdominal fat is metabolically and hormonally active in a way that peripheral fat is not - it both responds to falling estrogen and feeds back into how that fall feels. This is one more honest reason that the waistline conversation in midlife is about symptoms and long-term health, not appearance. And it reframes the goal: you cannot spot-reduce, but the usual boring levers (protein, resistance training, sleep, walking after meals) move exactly this fat depot.

The limits: cross-sectional, single-center, bioimpedance body-composition estimates, and a subjective symptom score. Mediation analysis in a snapshot of data cannot prove the estradiol pathway - it is a plausible mechanism, not a demonstrated one.

(Wang X, Yang D, Li J, Wang Y. Estradiol mediates the association of waist-to-hip ratio, but not body fat percentage, with menopause-related symptoms in Chinese women aged 40-60 years. Front Endocrinol (Lausanne), 2026. doi:10.3389/fendo.2026.1960475)

What is trending

The Menopause Society's 2026 Annual Meeting opens October 20-24 in San Diego, and the pre-meeting press releases are starting. The one making waves: a scoping review of ADHD medications (lisdexamfetamine and atomoxetine) for perimenopausal brain fog. The honest read: women reported feeling sharper and more on top of daily life, but objective cognitive tests did not move, and the Society itself says it is too early to recommend these medications for this use. If you see "ADHD drugs cure menopause brain fog" headlines in the next two weeks, now you know what the data actually says. Expect more meeting headlines - I will cover what matters.

The European estrogen shortage I have flagged before has escalated into a full supply story. Euronews reports that Spain's shortage of Lenzetto (a transdermal estradiol spray) cascaded into patches and gels (Evopad, Estradot, Bijuva are all affected), the EMA is weighing EU-coordinated measures, and the manufacturer admits it may not fully meet demand through 2027 - with relief in Spain expected to start only in late November. If you are in Europe and your pharmacy is out, do not wait and suffer silently: ask about alternative formulations now, before the queue gets longer.

The PMOS rename keeps rolling through the clinical press - Contemporary OB/GYN ran "PCOS is officially PMOS, but why?" this week - which tells me we are in the adoption phase now: the debate has moved from "should it change?" to "how do we implement it?" And an Australian piece on "unbridled rage" and other menopause symptoms doctors rarely discuss was widely shared - the conversation keeps widening past hot flashes, which is healthy.

One cross-reference: Issue 8, published two days ago, covered the new ACP guideline on treating hot flashes - if you missed it, that is the one to catch up on.

Until the next one,

Dr. Herman Weiss

Medical Disclaimer

The Pause Collective Science Review, Issue 7: September 28 - October 2, 2026

Dr. Herman Weiss — Fri, 09 Oct 2026 07:13:19 GMT

Photo by DIANA HAUAN on Unsplash

Dr. Herman Weiss

Oct 9, 2026

Welcome to Issue 7. Four papers this time. One asks why menopause medicine still runs on guesswork. One tells doctors how to prescribe hormone therapy to women with heart risk. One looks at an overlooked group, women with type 1 diabetes. And one, for my PMOS readers, asks whether it is how much fat you carry or where it sits. As always: I read the science so you don't have to, and I tell you where each study runs out of road.

PAPER 1. MENOPAUSE RESEARCH HAS BEEN STARVED, AND "HORMONE THERAPY" IS NOT ONE THING

Gravelsins LL, Perovic M, and colleagues including Wood Alexander M, McGovern AJ, Rabin JS, and Galea LAM. Reframing menopause and menopause hormone therapy as opportunities for healthy aging. Science, October 1, 2026. doi:10.1126/science.aeg5004

What it is. A review article in Science - not a new experiment. The authors pull together what is known about menopause as a turning point in aging.

What it says. Menopause covers up to about 40% of a woman's life, and up to 72 symptoms have been reported with it. Hot flashes and night sweats hit about 80% of women in the transition, and the average woman has seven symptoms at once. Yet the authors cite analyses showing that just 0.2% of federal health research funding in North America over 15 years went to menopause questions. Their other point is about hormone therapy: it comes in more than 200 varieties, differing by dose, type of estrogen and progestogen, and timing, and each has its own risk-benefit profile. They argue the research often lumps these together, and that this lumping changes what we conclude. Their answer is precision care: match treatment to your symptoms, your genetics, and your earlier hormone exposures. They also note that menopause type (natural versus surgical), timing, and symptom burden shape later-life disease risk.

What it means for you. When a headline says "hormone therapy raises risk" or "hormone therapy protects you," ask which hormone therapy. Oral or patch? Which progestogen? Started when? That question is the whole story, and it is why I keep telling you to bring the paper, not the headline, to your doctor.

Limits. A review is only as good as the studies it gathers, and the authors say themselves that the evidence on individual differences is thin. This is a framework for better research, not a new treatment rule.

For my PMOS readers: women with a PMOS history reach menopause with their own pattern - metabolic and androgen differences, and a different timeline of symptoms. A one-size menopause story was never written for you either. Under the same precision logic, your history belongs in the conversation with your doctor. (Cross-reference: the blood-protein aging work from this research group was in Issue 5.)

PAPER 2. HORMONE THERAPY WHEN YOU HAVE HEART RISK: A JOINT FIGO AND WORLD HEART FEDERATION POSITION

Benedetto C, Gulati M, Khadilkar SS, Maas AHEM, Frezet F, de Oliveira GMM, Genazzani AR, Divakar H, Poppas A, for FIGO and the World Heart Federation. Menopause Hormone Therapy in Women With Cardiovascular Risk Factors or Established Ischemic Heart Disease: A Joint FIGO and WHF Position Paper. Global Heart, September 22, 2026. doi:10.5334/gh.1576

What it is. A position paper - a consensus statement from gynecology and cardiology bodies, written to help both kinds of doctors counsel the same woman. No new patients were studied.

What it says. Systemic hormone therapy started early - ideally soon after symptoms begin and at most within 10 years of the final period - relieves symptoms and is associated with long-term benefits. Women with cardiovascular risk factors need a proper risk assessment first, so the type, dose, and route can be tailored. For women at high risk of blood clots, transdermal estrogen (the patch or gel), with micronized progesterone or dydrogesterone when a progestogen is needed, is considered the safest option. Women with established ischemic heart disease may still use systemic therapy for symptom relief if the risks and benefits are carefully reviewed; low-dose transdermal estrogen is the preferred choice. All other heart-protective care, including statins, should continue. The hardest cases call for cardiologists, gynecologists, and primary care working together.

What it means for you. Having high blood pressure, high cholesterol, or even heart disease is not an automatic "no" to hormone therapy - but it moves the decision into a tailored conversation, and it points toward the patch over the pill. This lines up with the Danish BMJ study we covered in Issue 5 on oral versus transdermal clot risk.

Limits. This is expert consensus, not a trial. It tells doctors how to reason; it cannot promise an outcome for any one woman. Your own history decides.

For my PMOS readers: PMOS carries metabolic and cardiovascular risk factors in many women. That is my reading, not a claim in this paper - the paper does not discuss PMOS. But if you have PMOS and are approaching perimenopause, your metabolic history is exactly the kind of risk-factor information this position paper says should be assessed before choosing a regimen.

PAPER 3. MENOPAUSE AND TYPE 1 DIABETES: THE GROUP THAT RESEARCH FORGOT

Bonhoure A, Yardley JE, Boudreau V, Lepine L, Moisan JM, Messier V, Brazeau AS, Rabasa-Lhoret R. Physical and psychosocial complications faced by postmenopausal women with type 1 diabetes: a cross-sectional BETTER analysis. Diabetes Research and Clinical Practice, 2026. doi:10.1016/j.diabres.2026.113484 (press coverage this week, Canadian Press, October 1)

What they studied. Records of 211 women with type 1 diabetes, aged 40 to 60, from the BETTER registry: 121 before menopause and 90 after. They compared physical complications, diabetes management, and mental health, adjusting the groups so they were comparable on other factors.

What they found. After menopause, the women had higher risks of cardiovascular disease (risk ratio 3.31), neuropathy (2.22), retinopathy (2.20), falls (2.64), and moderate-to-severe depressive symptoms (1.48). They were also less likely to be prescribed blood pressure medication (0.57) or cholesterol-lowering medication (0.68). Insulin doses, HbA1c, and low-blood-sugar frequency did not differ between the groups. Diabetes distress was lower after menopause (0.80).

What it means for you. If you have type 1 diabetes, menopause may be a point to re-check your eyes, nerves, heart risk, balance, and mood - and to ask whether your blood pressure and cholesterol are being treated as actively as they should be. Notice that blood sugar numbers did not explain the gap, which is exactly why it is easy to miss.

Limits. This is a snapshot, not a follow-up over time, so it cannot show that menopause caused any of these. Women who are older also have had diabetes longer, and the statistical adjustment cannot fully remove that. The group is small - the cardiovascular result had a wide margin (the confidence interval ran from 1.07 to 10.23), so treat the size of that number loosely. The authors themselves call for prospective studies.

PAPER 4. FOR MY PMOS COMMUNITY: IT MAY BE WHERE FAT SETTLES, NOT JUST HOW MUCH

Zhao G, Jin Y, Yang A, Yu X, Yan Z, Zhu S, Yang S, Wang W, Gao B, and colleagues. Causal adiposity and clinical validation of regional fat distribution in PMOS: a multi-modal analysis integrating GBD 2021, Mendelian randomization, and machine learning. International Journal of Obesity, published online September 7, 2026 (media coverage September 30). doi and abstract: https://www.nature.com/articles/s41366-026-02208-x

What they studied. Three things at once. First, global numbers from the Global Burden of Disease 2021 database. Second, a genetic method called Mendelian randomization, which uses inherited gene variants as a natural experiment to ask whether something causes a condition rather than just travels with it. Third, a machine-learning model in a clinical group with detailed body-composition scans.

What they found. In 2021, PMOS affected about 69.5 million women worldwide (1,757.8 per 100,000), the highest modeled incidence was at ages 10 to 14, and about 12.5 million infertility cases were attributed to it. In the genetic analysis, higher genetically predicted body mass index was linked to higher odds of PMOS (odds ratio 2.60), and so were body fat percentage (3.32), trunk fat mass (2.54), and left-leg fat mass (3.44). Fat-free mass - lean tissue - showed no significant link. The machine-learning model reached an AUC of 0.701, which is moderate, and the most influential features were left-leg fat, trunk fat, percent body fat, and protein mass.

What it means. The study supports the idea that body fat is a driver of PMOS, not just a bystander, and that body composition tells you more than BMI alone. It does not say fat is your fault, and it does not say weight loss is the only lever. Muscle was not the problem in this analysis.

Limits. I read the abstract; the full text is behind a paywall, so I could not check the methods in detail. Mendelian randomization depends on assumptions that are hard to prove. The numbers for different fat depots overlap heavily, because the genes that raise one raise the others - so "left leg" versus "trunk" should not be over-read. An AUC of 0.70 is not a diagnostic test. And global burden figures are modeled estimates.

For women heading into perimenopause: body composition shifts during the transition, and fat tends to move toward the abdomen. That is general physiology, not a finding of this paper, but it is why a PMOS history and the menopause transition deserve to be discussed together. Keeping muscle is a sensible goal either way, and lean mass was not linked to PMOS here.

WHAT'S TRENDING

What I can ground in coverage, and what I am inferring. I could not browse TikTok or Reddit directly this week, so what follows rests on news reporting about those platforms. Where I am reading between the lines, I say so.

1. The supplement price tag. Which?, the UK consumer group, published an audit on September 30 of 26 supplements marketed to perimenopausal and menopausal women, checking 78 active ingredients. It found many were close to a basic multivitamin with botanicals sprinkled in, often at doses too low to matter. Daily cost ran from 22p to 1.33 pounds, close to 500 pounds a year, versus 6p a day for a basic multivitamin - Which? puts the markup at about 20 times. One low-scoring product had no calcium or vitamin D. How it fits: this backs up the warnings I gave in Issue 1. Where the chatter and the evidence part ways: the marketing says "formulated for menopause"; the audit says the word "menopause" was often a price tag, not a formula. Note that this is a UK audit; check your own local products.

2. "Male menopause" on TikTok. SWNS reported September 30 that influencers claim all men go through "andropause," starting in the mid-thirties. A doctor quoted there says it does not exist as a predictable event, and that true late-onset low testosterone appears in about 2% of middle-aged men. That doctor runs a hormone-therapy clinic, so weigh the source. My inference: this is the same wave as the testosterone chatter I covered last week, now aimed at men. The evidence-based message is the same - low testosterone is a diagnosis made by a doctor, not a vibe.

3. The "meno-boom." Newsweek (September 30) describes menopause as a major social-media topic, citing insurer data of a roughly 200% one-day jump in TikTok searches on fertility and menopause on August 12. Doctors quoted say patients now arrive asking about oral versus transdermal estradiol and testosterone. That is a real shift: better-informed women. The gap: knowing the vocabulary is not the same as knowing the evidence, as this week's papers show.

4. A training gap. The Menopause Society announced September 30 a survey study in its journal Menopause finding that menopause education in US family-medicine residencies is broadly present but uneven, with no formal competency assessment (press release only; I did not read the paper). It is a plain reason many women feel dismissed. It is also a reason to arrive prepared.

5. PMOS after the awareness month. AJMC (October 1) reports the renaming consensus drew 56 organizations and 14,360 respondents, and quotes experts on persistent diagnostic delays. Its summary notes exercise, nutrient-dense eating, and metformin as first-line, and limited evidence for inositol supplements. Where it matches the evidence: the delay is real. Where I would stay careful: anything sold as a one-supplement fix.

That's the cycle. Bring your doctor the papers, not just the headlines.

Dr. Herman Weiss

Medical Disclaimer

Metformin before IVF does not improve pregnancy chances for women with PMOS - answers from 10,178 women

Dr. Herman Weiss — Wed, 07 Oct 2026 06:45:59 GMT

Photo by Suhyeon Choi on Unsplash

Dr. Herman Weiss

Oct 7, 2026

If you have PMOS (the condition formerly known as PCOS) and you have been through fertility treatment, there is a good chance someone handed you metformin along the way. The idea made sense on paper: metformin improves insulin resistance, insulin resistance sits at the heart of PMOS, so maybe metformin before IVF would improve ovulation and pregnancy rates. Doctors have prescribed it for this purpose for years.

This week we got the largest real-world answer so far, and it is a clear one.

The research. Cho, Park, Lee, Lim, Shin, and Kwak used South Korea's national health insurance database to study 10,178 women with PMOS who underwent their first fresh embryo transfer between 2017 and 2021. About one in five (2,149 women, 21.1%) had received metformin for ovulation induction in the 12 weeks before their ovarian stimulation. The team then compared outcomes between women who took metformin and women who did not, using a statistical weighting method to make the two groups as comparable as possible.

The result: metformin made no meaningful difference. Rates of successful egg retrieval (risk ratio 1.01), clinical pregnancy (risk ratio 1.05), and live birth (risk ratio 1.05, with a confidence interval of 0.99 to 1.12 that crosses the line of no effect) were essentially the same whether or not a woman took metformin. Just as important, there was no sign of harm: miscarriage (risk ratio 1.01) and preterm birth (risk ratio 0.99) were no different either.

Three subgroups showed a hint of possible benefit - women aged 35 and older, women on a specific stimulation protocol (the GnRH antagonist protocol), and women who took metformin for 30 days or more. These are signals to study further, not answers.

The plain-English meaning. For the average woman with PMOS heading into IVF, taking metformin beforehand does not raise the odds of bringing home a baby - and it does not lower them either. A very common, well-intentioned add-on turns out to be neutral for this particular job. That is valuable knowledge. It means one less pill to swallow for a purpose it does not serve, and it frees the conversation with your doctor to focus on what actually does move the needle.

What this does NOT mean. Metformin still has a real role in PMOS - as a metabolic medication, for insulin resistance and blood-sugar control, when your doctor judges you need it. This study asked a narrow question (does it help IVF succeed?) and answered that one. It was not testing metformin's metabolic uses.

And for the menopause half of our community, this is worth reading too. PMOS is a lifelong metabolic condition, and the same drug many of these women took hoping for a baby is the one whose real value is protecting their metabolic health for the decades that come after - including the transition into perimenopause, when insulin resistance tends to climb again. Getting clear on what each treatment is actually for, at each stage, is exactly the handoff this community is built on. And to our menopause readers: about one in eight women has PMOS. When you see how carefully this question was answered for them, expect the same standard of evidence for your own care.

The honest caveats. This is an observational study using insurance records, not a randomized trial. Women who were prescribed metformin probably differed from those who were not - often the ones with more obvious insulin resistance - and the researchers' statistical adjustments can only partly correct for that. The data come from one country's health system, cover only first fresh embryo transfers, and cannot tell us about dose or how faithfully women took the medication. The subgroup findings (age 35 and up, antagonist protocol, longer use) are hypothesis-generating at best; they need a proper trial. And full transparency: the journal page itself was not directly reachable this week, so this report is based on the published abstract and indexing records (doi:10.1002/cpt.70512, PMID 42827289).

What you gain from this. If you have PMOS and IVF is in your present or your future: do not start metformin expecting it to improve your chances - the best nationwide data says it does not. Do not stop it on your own either, especially if it was prescribed for insulin resistance or blood sugar; that is a different job, and this study says nothing against it. Bring the question to your doctor: "What am I taking this for?" If you are 35 or older, or on an antagonist protocol, ask whether the subgroup signal applies to you. And whatever stage you are at - trying to conceive, raising teenagers, or approaching the transition - the principle holds: every medication should have a job description, and you deserve to know what it is.

I read the science so you don't have to.

Dr. Herman Weiss

Medical Disclaimer

When menopause is brought on by medical treatment, the heart-risk story turns on one number: 45

Dr. Herman Weiss — Wed, 07 Oct 2026 06:41:40 GMT

Dr. Herman Weiss

Oct 7, 2026

Most conversations about menopause assume it arrives on its own schedule. For many women it does not. Surgery that removes the ovaries, or cancer treatment, can end ovarian function overnight, sometimes in a woman's thirties or forties. Doctors call this iatrogenic menopause - menopause caused by medical treatment. A new study in JAMA Network Open asks the question these women have been waiting on: what does it do to the heart, and does the age it happens at matter?

The research. Armeni, Erkan, and Kempegowda searched seven medical databases from January 2004 through March 2026 - 14,409 records - for studies comparing heart outcomes in women with iatrogenic menopause against women with natural menopause or women of the same age. Thirty-six studies qualified, covering 2,617,942 women, followed for a median of 16 years.

What they found. Overall, iatrogenic menopause was linked to higher risks: cardiovascular events 25% higher (pooled hazard ratio 1.25), coronary heart disease 48% higher (1.48), stroke 22% higher (1.22), and death from any cause 8% higher (1.08). Here is the part I want you to hold on to. The excess risk of dying - from heart disease and from any cause - showed up only when menopause came before age 45. Before 45, cardiovascular mortality was 20% higher (1.20) and all-cause mortality 15% higher (1.15). At or after 45, the numbers were essentially flat (0.95 and 0.99). In a further analysis, each 5 years later that menopause happened was linked to about an 11% lower risk of heart events and heart death combined (0.89). The authors read this as a period of elevated risk before 45, not a single cliff edge at one age.

What you gain from this. If you are facing a surgery or treatment that will end your ovarian function, this gives you a better question for your care team: not just "will this cause menopause," but "how early will it be, and what is our plan for my heart and my bones if it is before 45?" It also tells you that your risk is not fixed. Blood pressure, cholesterol, blood sugar, not smoking, and regular exercise matter at every age, and the earlier your menopause, the more reason to look at them closely and early. If you have already gone through an early iatrogenic menopause, this is a reason to make sure your cardiovascular risk is being checked, not a reason for alarm.

The honest caveats. This is a pooling of observational studies, not a trial, so it can show association, not proof that the menopause caused the extra risk. The women with iatrogenic menopause were on average about ten years older than the comparison groups in the studies pooled (55.5 versus 45.6 years), a gap that adjustment can only partly close. Women who need these treatments are also often ill to begin with, which can skew the picture. The 5-year-increment finding was a post hoc analysis, meaning it was not the planned main question. And the abstract does not tell us whether hormone therapy use after surgery changes any of this, so I cannot tell you that here.

For my PMOS readers: this paper does not study PMOS, so I will not pretend it does. But the lesson travels. If you have PMOS, you may already carry metabolic and cardiovascular risk factors, and if a medical treatment ever brings menopause on early, those two things would stack. That is my reading, not a finding of the study - but it is a good reason to know your numbers now, years before perimenopause arrives, and to tell any surgeon or oncologist about your full history.

That's the cycle. Bring your doctor the papers, not just the headlines.

Dr. Herman Weiss

(Armeni E, Erkan IBO, Kempegowda P. Age at Iatrogenic Menopause and Cardiovascular Morbidity and Mortality: A Systematic Review and Meta-Analysis. JAMA Network Open, 2026. doi:10.1001/jamanetworkopen.2026.37545)

Medical Disclaimer

Photo by Patty Brito on Unsplash

The Pause Collective Science Review, Issue 8: October 2-6, 2026

Dr. Herman Weiss — Wed, 07 Oct 2026 06:39:16 GMT

Welcome back to The Pause Collective Science Review, where I read the science so you don't have to. This was a big week. The American College of Physicians - one of the largest physician organizations in the United States - published a new guideline that says, clearly and at the top of the page, that hormone therapy should be the first treatment offered for bothersome hot flashes and night sweats. We also have an important long-term PMOS study that separates what body weight explains from what it does not, a practical guide in a major medical journal on what the PMOS name change means in the exam room, and a small but interesting trial of an oral, non-hormonal option for vaginal dryness and discomfort. Then, as always, what is actually trending - and how it holds up against the evidence.

1. A landmark guideline: the American College of Physicians says hormone therapy comes first for hot flashes

What it is. On October 6, the American College of Physicians (ACP) published a new clinical guideline on drug treatment for menopausal vasomotor symptoms - hot flashes and night sweats, which affect up to 80% of women around menopause. The guideline was built on a formal systematic review and meta-analysis and used the GRADE framework, the strictest standard for rating how certain the evidence is. An editorial by Drs. Regina Castaneda and Stephanie Faubion (past president of The Menopause Society) accompanied it.

What it recommends. For women seeking treatment for hot flashes and night sweats, ACP strongly recommends - on high-certainty evidence of net benefit:

First-line: estrogen plus progestogen for women with a uterus, or estrogen alone for women without a uterus.
Second-line (for women who cannot take or do not tolerate estrogen): an SNRI antidepressant - venlafaxine or desvenlafaxine.
Third-line: an SSRI (escitalopram or paroxetine), gabapentin, or one of the newer neurokinin receptor antagonists (fezolinetant or elinzanetant).

ACP also asks clinicians to bring up hot flashes themselves, because many women never do, and to choose treatment through shared decision-making that weighs benefits, harms, contraindications, other conditions, cost, and access.

What this means in plain English. For more than two decades after the Women's Health Initiative, many women and many doctors treated hormone therapy as a last resort. This guideline is the clearest statement yet from a major mainstream physician group that the evidence points the other way for most women with bothersome symptoms: hormone therapy is not the fallback. It is the first thing that should be offered, with non-hormonal medications as genuine, evidence-backed alternatives for women who cannot or do not want to use it. It also quietly legitimizes the newer non-hormonal drugs - fezolinetant and elinzanetant now sit inside a major guideline's recommended pathway.

The limits. The guideline covers hot flashes and night sweats only. It does not tell any individual woman which dose, form, or duration is right for her, and it does not apply to women with specific contraindications - that remains a personal conversation with your doctor. The evidence base is thinnest for women who cannot take estrogen and for the newest agents. And a guideline is a map, not a guarantee: what matters is how it changes the conversation in your own exam room.

For our PMOS readers. If you have PMOS, menopause is coming for you too, one day. It is worth knowing now what good care is supposed to look like when you get there - a doctor who asks about your symptoms and starts with the treatment that has the strongest evidence. The standard of care is being written in your favor.

Sources: Qaseem A, Mackey K, Yost J, et al. Pharmacologic Treatments for Females With Menopausal Vasomotor Symptoms: A Clinical Guideline From the American College of Physicians. Ann Intern Med. 2026. doi:10.7326/ANNALS-26-01205. Supporting systematic review: Diem S, Drake T, Kaka AS, et al. Ann Intern Med. 2026. doi:10.7326/ANNALS-26-00943. Editorial: Castaneda R, Faubion SS. Ann Intern Med. 2026. doi:10.7326/ANNALS-26-03184. ACP press release, October 5, 2026: https://www.acponline.org/acp-newsroom/acp-recommends-hormonal-therapy-as-a-first-line-treatment-for-menopausal-vasomotor-symptoms

2. Lean versus overweight PMOS, followed for years: weight raises the risk - but it does not create it

What it studied. A retrospective cohort of 1,500 women with Rotterdam-defined PMOS (500 lean, 1,000 overweight or obese) at a tertiary reproductive medicine center in China, enrolled between December 2020 and May 2022 and followed through December 2025 - a median of 4.3 years. The two main outcomes were new-onset metabolic syndrome and, in the subgroup going through fertility treatment (973 women, 1,432 IVF cycles), the cumulative live-birth rate.

What it found. Overweight and obese women fared worse on nearly every measure: new metabolic syndrome in 19.94% versus 9.22% of lean women (adjusted hazard ratio 2.33), new type 2 diabetes in 7.0% versus 2.6%, and a cumulative live-birth rate of 52.84% versus 70.49% (adjusted odds ratio 0.46 - roughly half the odds of taking home a baby). Pregnancy complications were also more common: gestational diabetes 23.49% versus 10.06%, hypertensive disorders of pregnancy 9.44% versus 2.83%, and macrosomia (very large babies) 11.65% versus 4.40%.

But the sentence in this paper that matters most is this one: lean PMOS was not metabolically benign. Nearly one in ten lean women developed metabolic syndrome in just over four years, and 2.6% developed type 2 diabetes - despite a normal BMI and far lower insulin resistance at baseline.

What this means in plain English. If you have PMOS and a higher body weight, this study says weight-stratified metabolic monitoring and structured pre-pregnancy weight care are worth real effort - the risk gap is large and it shows up in fertility outcomes, not just blood tests. And if you are lean with PMOS, do not let a normal BMI talk anyone - including your doctor - out of checking your metabolic health. PMOS is a metabolic condition at every size.

The limits. This is a retrospective, single-center study in Chinese women - BMI cutoffs and metabolic risk thresholds differ across populations, and a fertility-clinic population is not the average woman with PMOS. The live-birth outcome only applies to the IVF subgroup. Retrospective designs can show association, not prove cause. The findings fit the wider evidence (insulin resistance in PMOS exists independent of BMI), which strengthens them, but they should be read as one well-done cohort, not the final word.

For our menopause readers. This is why we say PMOS is a lifelong metabolic condition, not a fertility problem you age out of. The women in this study are heading toward perimenopause carrying this metabolic risk with them - and menopause adds its own cardiometabolic pressure on top. If you have a PMOS history and you are in your forties, your metabolic screening should not stop just because your periods did. This is exactly the handoff between the two halves of our community.

Source: Wen J, Guo R, Zuo Z. Metabolic and reproductive outcomes in lean versus overweight/obese phenotypes of polyendocrine metabolic ovarian syndrome: a retrospective cohort study with long-term follow-up. BMC Endocr Disord. 2026. doi:10.1186/s12902-026-02575-6. (Note: the journal page was not directly reachable this week; findings above are from the published abstract and indexing records.)

3. The PMOS name change reaches the clinic: CMAJ tells doctors how to actually use it

What it is. CMAJ, the Canadian Medical Association Journal - one of the most widely read general medical journals in the world - published a practice article on October 5 explaining the new PMOS name and, more importantly, what clinicians should do differently because of it.

What it says. The old name, PCOS, implied that ovarian cysts are the defining problem, that ultrasound is central to diagnosis, and that reproduction is the main concern. All three implications are wrong or incomplete. The article's practical advice: during the transition, clinicians should say "PMOS, formerly PCOS"; previous diagnoses remain valid and the diagnostic criteria have not changed; every patient should get baseline metabolic screening at diagnosis, with cardiometabolic risk factors rechecked every 1 to 3 years; and doctors should be careful that the word "metabolic" is not heard by patients as a coded comment about weight - insulin resistance in PMOS exists independent of body mass index, and surveillance is about prevention, not judgment.

What this means in plain English. The rename has now moved out of consensus documents and into the journals your family doctor actually reads. Expect the vocabulary in your exam room and your chart to shift before anything about your actual diagnosis does - and expect (or ask for) the metabolic conversation to come earlier and more often.

The limits. This is an educational practice article, not new data. Its job is to change habits, which takes years. We covered the rename itself, and the evidence behind it, in my four-part series earlier this fall - this is the implementation chapter, and it is worth watching.

Source: Mills G. Polyendocrine metabolic ovarian syndrome: a new name to support better treatment. CMAJ. 2026;198(34):E1341-E1342. doi:10.1503/cmaj.261239. https://www.cmaj.ca/content/198/34/E1341

4. A pill for vaginal dryness? A small trial of oral hyaluronic acid

What it studied. Genitourinary syndrome of menopause (GSM) - vaginal dryness, burning, discomfort with sex, urinary irritation - is common, chronic, and undertreated. This exploratory open-label trial randomized 60 postmenopausal women with vulvovaginal atrophy into three groups for 60 days: an oral full-spectrum sodium hyaluronate supplement, a vaginal hyaluronic acid ovule, or both combined.

What it found. Vaginal Health Index scores - a clinician-rated measure of vaginal tissue health - improved significantly in all three groups by day 30 and again by day 60. At day 60, the combination group scored highest, and the oral supplement alone outperformed the vaginal ovule alone. Patient-reported symptoms improved across the board, most in the oral and combination groups.

What this means in plain English. Hyaluronic acid is the same moisture-binding molecule used in skin care, and taken by mouth it appears to reach vaginal tissue. For women who cannot or do not want to use local estrogen, an oral, non-hormonal option that showed measurable benefit - especially combined with a local treatment - is genuinely interesting.

The limits. Be honest with yourself about what this is: 60 women, 60 days, no placebo group, everyone knew what they were taking, and it tested one specific commercial formulation. Symptom trials without a placebo tend to flatter the treatment. This is a promising signal that justifies a proper blinded trial - not a reason to replace standard care, which remains vaginal estrogen or other proven GSM treatments.

Source: Governini L, Vicariotto F, De Leo V, Nobile V. Oral full-spectrum sodium hyaluronate for vulvovaginal atrophy in postmenopausal women: a randomized, parallel-group clinical trial. Nutr J. 2026. doi:10.1186/s12937-026-01404-9. (Note: findings are from the published abstract; the full journal page was not directly reachable this week.)

What is trending - and how it holds up

The ACP guideline is the menopause story of the week. Coverage in Healio, MedPageToday, and ACP's own newsroom (all October 5) has been, for once, largely accurate: "hormone therapy first for hot flashes" is what the guideline actually says. Expect this to dominate menopause social media for days. Where I would add caution: the headline applies to hot flashes and night sweats in women without contraindications. It is not a blanket "everyone should take hormones," and it says nothing about hormones for brain fog, weight, or anti-aging. (Grounded: ACP newsroom, Healio, MedPageToday coverage.)

The world menopause congress just wrapped. The International Menopause Society's 20th World Congress ran September 29 to October 3 in Rio de Janeiro. The headline-making item out of it: Astellas presented preliminary real-world data from its Phase 4 OPTION-VMS study of fezolinetant (VEOZAH), reporting improvement in bothersome hot flashes by week 12 and better sleep - including an average of 2.6 fewer nighttime awakenings per night at week 12, measured both by questionnaires and by a medical-grade wearable. Sleep disturbance affects an estimated 40-60% of menopausal women, so the interest is understandable. The honest caveats: this is a company press release about a preliminary analysis, the study was not designed to compare fezolinetant against other treatments, and real-world improvement from baseline is not the same as proof of superiority. Still, objective sleep data from wearables is a welcome step beyond questionnaires. (Grounded: imsociety.org and imsrio2026.com for the congress; the Astellas/PRNewswire release of October 2 for the data.)

The PMOS rename keeps rolling. This week the story reached CMAJ (annotated above), a Medscape primary-care explainer (October 5), and further science-media coverage. On r/PCOS, the community debate is real and unresolved: the May announcement thread drew thousands of upvotes, while a July thread titled "Am I the only one who hates the new PMOS name?" captured the other side - some women hear "PMOS" as too close to "PMS," and worry it will be used to dismiss them. Both things can be true: the name is more accurate, and transitions are uncomfortable. My take, as I wrote in the rename series: use "PMOS, formerly PCOS," and keep the patient at the center. (Grounded: the cited articles and publicly visible Reddit threads via search; I did not browse Reddit directly this week.)

What your TikTok feed is and is not showing you. A study published September 29 in the journal Menopause analyzed 834 videos from the 10 most influential menopause creators on TikTok. Sexual symptoms were rarely mentioned - vaginal dryness in 3.5% of videos, libido changes in 7.9%, pain with sex in 2.0% - while mood changes (31.2%) and hot flashes (13.5%) dominated. Half the videos (51.6%) were about validating symptoms or empowerment, 19.3% offered management strategies, and 13.2% included product endorsements. Only 1 of the 10 most influential creators was a medical professional. Validation matters - feeling believed is not nothing. But if your feed is where you learn about menopause, you are seeing an incomplete picture that skews away from sexual health and toward whoever has the biggest following. (Grounded: Hariharan L, Ahsan SJ, Rowen TS. Menopause. 2026. doi:10.1097/gme.0000000000002938. I did not browse TikTok directly; this is the published analysis.)

One to file under "the press caught up." Canadian media (CTV News / The Canadian Press, October 1) covered how women's physical and mental health can worsen after menopause in type 1 diabetes. That is the BETTER registry analysis we annotated in last week's review - good to see it getting the attention it deserves. And Sunnybrook's October 1 press release on blood markers linking menopause and brain aging is the Nature Medicine proteomics study we covered in Issue 5; the science is the same, the headlines are new.

A note on method, as always: the trending items above are grounded in news coverage, press releases, and publicly visible discussion threads found through search. Where I have not browsed a platform directly, I say so, and where something is my interpretation rather than a fact, I mark it as such.

That is the week in science. The big picture: mainstream medicine is moving, visibly, toward taking both menopause symptoms and PMOS as seriously as they deserve - a first-line hormone therapy recommendation from America's internists, metabolic screening woven into the PMOS name change, and a global congress paying attention to sleep. We will keep reading. You keep asking questions.

Until next time,

Dr. Herman Weiss

Medical Disclaimer

Photo by Look Studio on Unsplash

Everyone is selling testosterone for menopause brain fog. The first proper count of the evidence just came out - and the honest answer is we don't know.

Dr. Herman Weiss — Thu, 01 Oct 2026 06:04:45 GMT

Dr. Herman Weiss

Oct 1, 2026

Photo by kevin turcios on Unsplash

Scroll social media this month and you'll hear that testosterone sharpens the menopausal brain - clearer thinking, no more brain fog, your old self back. I told you about the FDA's first-ever meeting on testosterone for women two weeks ago, and the hype has only grown since. So the timing could not be better for what just published: the first systematic review and meta-analysis to gather every study ever done on testosterone therapy and cognition in menopause, and pool what they found.

The research. Alexandra Faulkner, Aimee Spector, and colleagues at University College London searched five medical databases from their beginnings through March 2025 - 3,880 records - for studies testing testosterone therapy against thinking and memory in the menopause transition and postmenopause. After screening, five studies qualified. Three, covering 244 postmenopausal women, could be pooled statistically across three domains: executive function (planning, attention, decision-making), verbal learning and memory, and visuospatial learning and memory.

What they found. Nothing - carefully. The pooled effects of testosterone on every cognitive domain were statistically indistinguishable from zero, with effect sizes mostly close to zero. And here is the part the hype will skip: the authors are explicit that this is not proof testosterone does nothing. It is proof we don't have the data. Five small studies, only 244 women in the pooled analysis, not a single study on subjective brain fog - the thing women actually complain about - and not one study in perimenopause, the stage where cognitive symptoms seem to hit hardest. The verdict is "insufficient evidence," not "no effect."

What you gain from this. If someone - a clinic, an influencer, a friend with a pellet guy - promises you testosterone will clear your brain fog, you now know exactly what the entire scientific literature can and cannot back: nothing, either way, yet. That protects your wallet and your expectations. It also sharpens what the hormone is actually for: the evidence-backed use remains low sexual desire that causes distress, as the FDA panel discussed. For brain fog itself, the levers with real evidence behind them are unglamorous - sleep, exercise, treating depression and anxiety, checking thyroid and B12, and reviewing medications that fog the brain. If testosterone trials for cognition come - and after this paper, expect them - I'll read them for you.

For my PMOS readers: you have a particular reason to read this one. The hormone being marketed to menopausal women as a missing ingredient is the one your body often overproduces - elevated androgens are part of the PMOS picture, not a deficiency to correct. So the cure-all framing was never aimed at your biology, and adding androgens is not your brain-fog fix either. Your cognitive complaints deserve the same evidence-first workup, and the same honesty about what isn't proven.

That's the cycle. Bring your doctor the papers, not just the headlines.

Dr. Herman Weiss

(Faulkner A, Desai R, Keay N, Ellahi SA, Aimee S. Testosterone Therapy for Cognition in Menopause: Systematic review and meta-analysis. Reproduction and Fertility, published online Sep 29, 2026. doi:10.1530/RAF-26-0080)

Medical Disclaimer

The Pause Collective Science Review, Issue 6: September 25-29, 2026

Dr. Herman Weiss — Wed, 30 Sep 2026 12:04:24 GMT

Dr. Herman Weiss

Sep 30, 2026

Photo by National Cancer Institute on Unsplash

Three papers this week, and they rhyme. One shows that the biggest women's-health transition is nearly invisible in American medical records. Two are about PMOS: one finds a gut-bacteria signature that works in the lab and stumbles in the wild, and one asks women themselves why healthy habits fall apart - and gets an answer every doctor should memorize. Then the week in social media, where testosterone is being sold as a cure-all again.

Paper 1: Menopause barely exists in your medical record. Researchers at the University of Colorado, including Audrey Hendricks and Nanette Santoro, asked a simple question inside the NIH's All of Us Research Program: when a woman goes through menopause, does her chart notice? They analyzed surveys, electronic health records, and genomic data from roughly 396,000 women. Survey responses captured about 193,000 menopause observations. The medical records? About 28,000 diagnoses - seven times fewer. Nearly every woman who had a menopause code in her record also reported the transition in her survey, so the records that exist are accurate. They're just mostly absent. What this means in plain English: if you assume your doctor's system knows where you are in the transition, it probably doesn't. Menopause status shapes how we read your cholesterol, your bone density, your bleeding, your cancer screening - and it's missing from the record most of the time. Until systems catch up, the fix is low-tech: say it out loud at every appointment. "I'm perimenopausal" belongs in the room even if it never makes the chart. Limits: this is one research program's data, it describes documentation rather than care quality, and the authors frame it as groundwork for research design, not a verdict on your clinic. For my PMOS readers, note the timing: your condition is mid-rename from PCOS to PMOS, which means two sets of codes and an even thinner documentation trail. If a transition half of humanity goes through is invisible, a renamed syndrome doesn't stand a chance - carry your history in your own words. (Staples JW, White SL, Giacalone A, Pozdeyev NV, Sammel MD, Stranger BE, Valencia CI, Santoro NF, Hendricks AE. Menopause in the All of Us Research Program: a descriptive summary of electronic health record and survey response across sociodemographic characteristics. Menopause, 2026. Authors' summary: The Conversation, Sep 28, 2026.)

Paper 2: The PMOS gut signature is real - and it doesn't travel. A team led by P. Huang pooled stool metagenomic data from three independent cohorts, 169 women in all, and rebuilt the bacterial world inside them from scratch: 540 reconstructed bacterial genomes, 32 of them apparently new to science. Women with PCOS/PMOS carried fewer species overall, a less interconnected microbial community, and eleven species at different abundance - including higher levels of two common gut residents, Phocaeicola vulgatus and Bacteroides uniformis. The bacterial genomes more common in PMOS were loaded with sugar-import machinery, which fits the insulin-resistance biology at the condition's core. Then the authors did the thing I wish every microbiome paper did: they trained a model to spot PMOS from gut data and tested it on women it had never seen. Within one cohort it worked well (AUC 0.757). Across cohorts it stumbled. Their own conclusion: promising signal, not ready for clinical use, external validation required. So file this under "real biology, no action yet" - no probiotic, no stool test, no gut protocol follows from it today. What you gain: confirmation that the gut is statistically entangled with PMOS, and a BS detector for anyone selling you a microbiome cure. For the menopause side of our community: remember the gut-barrier markers we covered that shift through the menopause transition (post #3) - the gut is turning out to be a character in both of our stories, and women carrying PMOS into perimenopause will hear gut claims aimed at them from both directions. Now you know what "validated" should mean before you believe one. (Huang P, Zhang M, Li Q, Xu H, Shou H. Altered gut microbiota composition and function potential in polycystic ovary syndrome: a multicohort metagenome-assembled genomes study. European Journal of Obstetrics & Gynecology and Reproductive Biology, 2026. doi:10.1016/j.ejogrb.2026.115453)

Paper 3: Why the lifestyle advice falls apart - asked the women living it. We tell women with PMOS to eat differently and move more, and then we act surprised when it doesn't stick. A team at Central South University in Changsha sat down with 20 women with PMOS plus 13 doctors and 4 nurses and built, from their interviews, a map of how behavior change actually happens: intention, adoption, maintenance - and disengagement, a state that can swallow you at any point. Intention comes from real concerns: fertility, symptoms, self-esteem. Adoption needs self-efficacy, usable health information, resources, and support. The few who reached maintenance had goal-setting, self-regulation, identity, and positive feedback working for them. Most participants disengaged somewhere along the way - not from weakness, but because, as corresponding author Shujuan Zhu puts it, restraining factors outweighed the supports. Time, cost, complexity, disease burden. Her line deserves to be taped inside every chart: disengagement "should not simply be viewed as a personal failure of willpower." What you gain: if you've started and stopped, you are the norm in this data, not the exception - and the fix is structural (smaller steps, support, stage-matched advice), not more shame. For menopause readers: swap "PMOS" for "perimenopause" and every sentence still holds - the same intention-adoption-maintenance climb, the same cliff. Limits: 37 interviews, one province in China, a framework to be tested elsewhere rather than settled truth. But it matches what the larger PMOS lifestyle meta-analysis told us in Issue 5, and it explains the "why" behind those numbers. (Shen Q, Zhang X, Peng E, Qu J, Zhu S, Lei J. Revealing the complexity of health behavior change among women with polycystic ovary syndrome: a qualitative grounded theory study. Journal of Nutrition Education and Behavior, 2026. doi:10.1016/j.jneb.2026.07.008)

One cross-reference: Sunday's post covered the orforglipron analysis presented at EASD this week - a daily GLP-1 pill with similar weight loss across all three menopausal stages. It's on the site; I won't re-review it here.

What social media is saying. Four currents this week, two on each side of our community. First, testosterone is being sold as a menopause cure-all again. CBC News ran a full investigation (Sep 26): influencers and some physicians tout it for everything from libido to night sweats, off-label use is booming, and the researchers they interviewed pushed back hard - the evidence supports testosterone for one indication, low desire causing distress, and not for mood, cognition, or general vitality. UBC's Jerilynn Prior was blunt: there's no physiological reason for most menopausal women to take it. The grounded part: the FDA's September 17 workshop (covered here as post #4) has opened a formal evaluation, with public comment running into mid-October - regulation is following the hype. Where chatter meets evidence: desire, yes; cure-all, no. Second, muscle. Dr. Gabrielle Lyon's podcast episode "Menopause Is a Muscle Problem" (Sep 24) is everywhere this week: lean mass falls fastest in perimenopause, the slide may start near 35, and no pill or patch rebuilds it - her prescription is resistance training two to three days a week plus protein. That message matches the evidence direction (and Sunday's post made the same muscle point about GLP-1 weight loss). Just clock the commercial layer: the episode funnels to a paid challenge with a discount code. Good advice, sold. Third, the supplement boom has a new flagship: Ritual launched a perimenopause capsule pairing shatavari extract with DIM (Sep 28). Neither ingredient has anything like the trial evidence we require here - compare the chasteberry RCT from post #5, where at least a real trial existed. Marketing is sprinting ahead of data again. Fourth, PMOS has a new kind of voice: Dr. Asima Ahmad, a reproductive endocrinologist, wrote in Women's Health (Sep 28) about diagnosing herself with PMOS in her twenties after years of dismissal - and cites the numbers behind her story: a third of women wait more than two years for diagnosis, nearly half see three or more clinicians first. The rename (14 years of work, 56 organizations, 22,000 survey responses) keeps reaching bigger stages, and now the specialists are telling their own stories. That is how a name actually moves.

That's the week. Bring your doctor the papers, not just the headlines.

Dr. Herman Weiss

Medical Disclaimer

A weight-loss pill that works the same before, during, and after menopause: new data this week. Here's what it means - and what it can't tell you.

Dr. Herman Weiss — Sun, 27 Sep 2026 08:02:11 GMT

Dr. Herman Weiss

Sep 27, 2026

Photo by John Arano on Unsplash

The question comes up in my world constantly: do the new weight-loss medications still work once your hormones change? Menopause makes weight genuinely harder - estrogen loss pushes fat toward the middle, muscle gets easier to lose than to keep, and many women feel like their body changed the rules without telling them. So when a drug company ran the numbers on whether menopause blunts the effect of its new daily weight-loss pill, the answer mattered. The answer arrived this week: no, it doesn't.

The research. Hoffman and colleagues at Eli Lilly took the data from ATTAIN-1 and ATTAIN-2 - the two big trials of orforglipron, a once-daily pill in the GLP-1 family (the same drug family as semaglutide, but a small-molecule tablet rather than a weekly injection) - and re-analyzed them by menopausal stage. Women in the trials had obesity, or overweight with at least one weight-related condition; the analysis sorted them into premenopausal, perimenopausal, and postmenopausal groups, with 142 to 225 women in each, and followed them for 72 weeks. The results are being presented this week at the European Association for the Study of Diabetes annual meeting in Milan.

What they found. The drug worked the same everywhere. Women lost up to 14% of their body weight on orforglipron, with no meaningful difference between the three menopausal stages, in both trials. Waist circumference fell by up to 12.5 cm (about 5 inches) across groups. Up to 83% of women on the drug lost at least 5% of their body weight, versus 30% on placebo. The menopause transition - the thing that makes weight feel like an uphill fight - did not blunt the medication's effect at all.

What you gain from this. If you're in or past the menopause transition and you've wondered whether these medications are "for" women like you, this is the first clean answer: the biology of midlife doesn't cancel the drug. Now the fine print, because there always is some. This is an analysis run by the manufacturer, presented at a conference - it hasn't been through full peer review as its own paper yet. Orforglipron itself is still an investigational drug; you cannot get a prescription for it today. And the trials measured weight and waistlines, not the things you actually live in: we don't know from this analysis how much of the lost weight was muscle, and muscle is the tissue you can least afford to lose after fifty. If you ever do take a medication like this, the non-negotiables travel with it - enough protein, and resistance training two to three times a week. The drug shrinks the number on the scale; only you decide how much of what's left is strong.

For my PMOS readers: you know this drug family already - GLP-1 medications are increasingly part of the PCOS/PMOS conversation because they hit the insulin resistance at the center of the condition. This analysis didn't include PMOS-specific groups, so it can't answer your question directly. But if you're a woman with PMOS heading toward perimenopause, here's the useful takeaway: the midlife hormone shift doesn't appear to weaken these drugs, and your metabolic starting point is exactly the terrain they were built for. When PMOS-specific trials land - and they will - I'll walk you through those too.

That's the cycle. Bring your doctor the papers, not just the headlines.

Dr. Herman Weiss

(Hoffman HT, et al. Orforglipron in women by menopausal stage: analyses of ATTAIN-1 and ATTAIN-2. European Association for the Study of Diabetes annual meeting, Milan, Sept 28-Oct 2, 2026. via EASD release, medicalxpress.com)

Medical Disclaimer

The Pause Collective Science Review, Issue 5: September 22-25, 2026

Dr. Herman Weiss — Fri, 25 Sep 2026 10:20:18 GMT

Dr. Herman Weiss

Photo by Logan Gutierrez on Unsplash

Sep 25, 2026

Three papers this cycle, each with a practical edge: a huge Danish study that finally puts clean numbers on the pill-versus-patch question, the most complete analysis yet of what diet and exercise actually accomplish in PMOS, and a Nature Medicine paper that found the molecular fingerprint menopause leaves in blood - and tied it to brain aging. Then your feeds: women are buying gray-market peptides with code names, and PMOS just had its biggest mainstream media week since the renaming. I read the science so you don't have to.

Oral vs transdermal hormone therapy: the cleanest clot numbers yet. Researchers mined Denmark's national health registries for every woman aged 50 to 69 between 2003 and 2021 with a first blood clot, stroke, or heart attack - nearly 10,000 clot cases, over 18,000 strokes, almost 12,000 heart attacks - and matched each against women without those events, then compared their prescriptions. Published September 23 in The BMJ. The headline: oral hormone therapy was linked to higher clot risk regardless of dose or how long it was used, while patches, gels, and sprays showed no general increase in clot risk at any dose or duration. The absolute numbers keep it honest: one extra clot per year for every 1,055 women on oral therapy, one extra stroke per 1,642, one extra heart attack per 3,846 - and the stroke and heart attack risk lived almost entirely in high-dose pills (above 1 mg estradiol a day) taken for more than a year. What this means: small risks, real differences by route. If you're on oral therapy and have any clot risk factors, this study is a good reason to ask your doctor whether a patch would do the same job with less baggage. The limits: registries can't capture every confounder, the transdermal group was smaller, and one subgroup (combined cyclic therapy through the skin) showed a heart-attack signal on sparse data - worth watching, not worth panicking over. For my PMOS readers, a detail worth knowing: this study deliberately excluded women with a PCOS diagnosis. The biggest safety dataset we have doesn't directly include you, and your baseline clot risk already runs higher than average - so the route question deserves an explicit conversation, not an assumption. (Contemporary menopausal hormone therapy and thrombotic disease: nationwide nested case-control study. BMJ. 2026. doi:10.1136/bmj-2026-100688)

Lifestyle treatment in PMOS: what the trials actually add up to. Olalere and colleagues updated the evidence base behind the international PMOS guideline with every randomized trial of diet, exercise, or behavioral programs - 34 trials, 1,871 women, published September 23 in PLOS Medicine. Women in lifestyle programs were four times as likely to regain regular cycles (odds ratio 4.03), and lost on average 2.4 cm off waist circumference, with small but real improvements in fasting glucose and fasting insulin. The useful detail: different tools did different jobs - exercise was best for waist size and insulin, diet was best for glucose, and women with overweight saw the widest benefits, including lower testosterone and better cholesterol. What this means: lifestyle treatment in PMOS is not a lecture, it's a therapy with measurable effects - but the honest caveats travel with it. That fourfold increase in regular cycles comes from just 5 small trials with a wide confidence range, a third of the studies had a high risk of bias, and the trials disagreed with each other a lot. And reproductive outcomes beyond cycle regularity - pregnancy, live birth - were barely reported at all. For my menopause readers: notice what's happening here. The first-line therapy for the most common hormone condition of young women is the same one your doctor gives you at fifty - food, movement, behavior - and the evidence says it works modestly in both decades, which is why how it's prescribed matters as much as what. (Olalere O, et al. PLOS Med. 2026. doi:10.1371/journal.pmed.1004887)

The blood signature of menopause, mapped to the aging brain. Wood Alexander, Rabin, and colleagues asked a deceptively simple question in Nature Medicine (September 22): does menopause leave a readable fingerprint in blood proteins, and does it connect to brain aging? In 80 carefully staged women aged 43 to 58, they found menopause-linked disruption in inflammatory, synaptic, metabolic, and Alzheimer-related protein pathways - and these shifts tracked with hormone levels more strongly than with age itself. Women with hot flashes showed especially strong pro-inflammatory signals. The finding held up in a 2,814-woman validation sample, and across four cohorts totaling nearly 12,000 older women, a higher "menopause proteomic score" predicted worse cognitive aging and higher dementia risk. What this means: menopause is not just a reproductive event - it's a whole-body molecular event that shows up in the blood and lines up with the biology of the aging brain. Down the road, this is how a midlife blood test for brain-risk could actually get built. The limits: associations, not causes - nobody knows yet whether calming the protein shifts (with hormones, exercise, or anything else) changes the dementia outcome, and the discovery group was small. For my PMOS readers: chronic low-grade inflammation is already a feature of PMOS in your twenties and thirties. Menopause appears to stack a second inflammatory shift on top. Managing inflammation and metabolism early isn't vanity - it's brain insurance. (Wood Alexander M, Rabin JS, et al. Nat Med. 2026. doi:10.1038/s41591-026-04648-4)

What's trending this week - and how it holds up. Two things are moving. First, grounded: the New York Post published an investigation into women treating menopause symptoms with gray-market peptides bought online - "research use only" vials, self-designed protocols, and a whole coded vocabulary ("peppers" for peptides, "ratatouille" for retatrutide) built to dodge TikTok and Instagram moderation. A Nautilus piece the same week maps how fast peptide content is spreading on social platforms. The honest read: none of these products has a menopause trial behind it, dosing is guesswork, and quality control is nil. But I'd rather be honest about why it's happening - the same care gap the Senate heard about two weeks ago. When the system leaves women symptomatic and unheard, the gray market writes its own protocols. Bring me the vial before you inject it; I'd rather know than have you hide it. Second, grounded: PMOS had its biggest mainstream week since the renaming - National Geographic asked "Are We Treating PMOS All Wrong?" and Women's Health ran new survey research on diagnostic delays, weight bias, and eating-disorder risk in PMOS care, finding years-long delays and advice that often amounts to "lose weight" delivered as blame. Where the chatter matches the evidence: the lifestyle meta-analysis above says diet and exercise genuinely help - and the survey data says how that advice is delivered is breaking patients. Both are true at once. That's the whole argument for treating these two audiences - and their doctors - as one community.

That's the cycle. Bring your doctor the papers, not just the headlines - and if the headlines come in code words, bring those too.

Dr. Herman Weiss

Medical Disclaimer

One infusion, 94% fewer fractures: a cell therapy for osteoporosis just passed its first human test. Read the fine print with me.

Dr. Herman Weiss — Wed, 23 Sep 2026 06:43:56 GMT

Dr. Herman Weiss

Photo by BHLNZ - Biodiversity Heritage Library NZ on Unsplash

Sep 23, 2026

One in three women over 50 will break a bone because of osteoporosis. Around the world that's about 10 million fractures a year - one every three seconds. Every pill and injection we have works by slowing the loss. None of them rebuilds a skeleton, and all of them have to be taken for the rest of your life. This month, a team in Spain reported something different in the journal Cell: ten women with advanced osteoporosis received a single infusion of their own bone marrow cells, and their fractures nearly stopped. As always, what this shows and what it can't show are equally useful to you.

The research. Moraleda, Linares, and colleagues ran the first human trial of a clever fix to an old problem (ClinicalTrials.gov NCT02566655). Bone marrow holds the cells that build bone, and they grow easily in a lab - but earlier attempts to infuse them went nowhere, because blood vessels inside bone have a gate, and these repair cells don't carry the pass that lets them dock. The pass turns out to be a single sugar pattern on the cell surface. So the team drew each woman's marrow, grew the cells for several weeks, and briefly treated them with a natural enzyme plus that one sugar. Nothing inside the cell was touched, no gene was edited, and the added sugar wears off on its own within two days - just long enough for the cells to reach bone and settle in.

What they found. Ten women, aged 50 to 75, all with advanced osteoporosis, all having already broken at least one bone. One infusion each, home the next day, and not a single reaction to the treatment. Broken bones across the group fell from eight a year to one every other year - that's the 94% drop behind the headlines. Hip bone samples taken four months after the infusion held nearly twice as much bone tissue as samples taken on treatment day. Detailed wrist scans at two years showed better internal bone structure. The women reported about a third less pain and noticeably easier daily movement. And the safety record so far is clean: across six years of watching, no cancers, no bone growing in the wrong places, no serious adverse events.

What you gain from this. For the first time, there's realistic hope that a one-time treatment could rebuild bone instead of just slowing its loss - and the cells came from older women with diseased marrow, the kind long assumed to be too worn out to work. They rebuilt bone anyway. Now the honest caveats, and they matter: ten women, one hospital, no control group. The 94% compares each woman's fracture rate before and after her infusion, and people inside trials often do better than people outside them for reasons that have nothing to do with the treatment. Larger controlled trials will take years, and this is not coming to a clinic near you soon. So the actionable line for today hasn't moved: ask about a DEXA scan, lift something heavy regularly, get your vitamin D checked, and if your doctor has already offered you bone medication, take that conversation seriously - close to a third of the women who should be on these drugs aren't, and they work best before the first fracture, not after.

For my PMOS readers: you may have heard that higher androgen levels protect your bones while you're young. Partly true - but it's not a pension plan. Estrogen loss at menopause comes for you exactly as it comes for everyone else, and the baggage that often travels with PMOS - vitamin D deficiency, less weight-bearing exercise - can quietly eat whatever advantage you started with. Watch your bones into midlife with the same suspicion you bring to your blood sugar.

That's the cycle. Bring your doctor the papers, not just the headlines.

Dr. Herman Weiss

(Moraleda JM, Linares LF, et al. Glycocalyx-edited mesenchymal stem/stromal cell therapy in advanced osteoporosis. Cell. 2026. doi:10.1016/j.cell.2026.08.017)

Medical Disclaimer

The Pause Collective Science Review, Issue 4: September 20-22, 2026

Dr. Herman Weiss — Tue, 22 Sep 2026 07:14:09 GMT

Dr. Herman Weiss

Photo by Venti Views on Unsplash

Sep 22, 2026

Three papers earned your time this cycle: the largest analysis ever of hormone therapy and blood sugar, the first large prospective study of PMOS in pregnancy since the renaming, and a randomized trial that turns "exercise is good for your brain" into an actual prescription. Then we'll look at what your feeds are serving - the Senate finally held a menopause hearing, and creatine is having a moment. I read the science so you don't have to.

Hormone therapy and type 2 diabetes: a small effect, honestly reported. Liang and colleagues pulled together every randomized trial and cohort study they could find on menopause hormone therapy (MHT) and glucose metabolism - 49 studies, nearly 1.5 million women, published September 18 in Diabetologia. Among women without diabetes, MHT users had lower fasting insulin and a 17% lower relative risk of developing type 2 diabetes (risk ratio 0.83). Among women who already had diabetes, MHT modestly improved fasting glucose, HbA1c (by about half a percent), LDL cholesterol, and systolic blood pressure. Now the honest part, and credit to the authors for stating it plainly: they rate the certainty of evidence for the headline diabetes finding "very low," only 7 of the 49 studies had a low risk of bias, and their own conclusion is that the effects, while real, are too small to be clinically meaningful. So here is what this means for you: MHT is a symptom treatment, not a metabolic one. If you take it for hot flashes and your blood sugar drifts a little better, that's a bonus - not a reason to start, and not a reason to skip the boring fundamentals. For my PMOS readers, this one matters directly: PMOS is at its core an insulin-resistance condition, and you carry an elevated diabetes risk into midlife. This analysis tells you what hormone therapy at menopause will not do about that. Muscle, movement, sleep, and food remain the fix. (Liang C, et al. Diabetologia. 2026. doi:10.1007/s00125-026-06856-6)

PMOS in pregnancy: the first big prospective numbers under the new name. Neven and colleagues analyzed 3,645 pregnant women enrolled in the international TOBOGM trial - all already at risk for high blood sugar - and found that 17.1% met criteria for PMOS. Compared with the other women, the PMOS group had 37% higher adjusted odds of early gestational diabetes, 28% higher odds of a composite of adverse newborn outcomes, and 32% higher odds of the baby needing intensive or special care, with delivery about a day and a half earlier on average. The detail I find most important: these risks did not shrink after adjusting for body weight, and they did not vary by ethnicity. The syndrome itself carries the risk, not just the weight that often travels with it. What this means: PMOS should be treated as its own pregnancy risk factor - earlier diabetes screening and closer fetal monitoring, not extra worry. The limits: this was an observational cohort nested inside a trial, PMOS was identified by clinical criteria rather than one universal test, and the women were all preselected for metabolic risk, so these numbers don't describe every pregnancy with PMOS. For my perimenopause and menopause readers: early gestational diabetes is not only a pregnancy event. It is one of the strongest early flags we have for lifetime type 2 diabetes and cardiovascular risk. If this was you twenty years ago, midlife is exactly when that flag should change how closely you and your doctor watch blood sugar, blood pressure, and arteries. (Neven ACH, et al. Diabetes Care. 2026. PMID: 42747940)

Exercise and the menopause brain: from advice to prescription. Sanz Simon and colleagues at Rutgers, with collaborators at Einstein and Columbia, randomized 93 women aged 20 to 67 - all with below-average fitness, none regular exercisers - to six months of either aerobic exercise or a stretching-and-toning program. The postmenopausal women in the aerobic group improved their executive function (task-switching speed, error management) more than both the stretching group and the premenopausal women doing the identical program. The gains were measurable at three months and still growing at six. Memory and processing speed didn't budge - the benefit was specific to executive function, the set of skills you use to plan, switch tasks, and stay organized. What this means: the menopause transition may be a window when the brain is especially responsive to aerobic training, and the studied dose is doable - 45 minutes of moderate cardio, three to four times a week, after a short warm-up. Brisk walking counts. The limits: 93 women is small, about 7 in 10 completed the full program, and we cannot yet say whether better task-switching at six months means less dementia at seventy-five. For my PMOS readers: brain fog is one of your community's most common complaints too, and this is the rare intervention that treats that and insulin resistance at the same time. (Sanz Simon S, et al. J Alzheimers Dis. 2026. rutgers.edu/news)

What's trending this week - and how it holds up. Three things are moving. First, grounded: on September 16 the US Senate Special Committee on Aging held Congress's first-ever hearing devoted entirely to menopause - we flagged the run-up in Issue 2, and now it has happened. The tangible outcome: Senators Gillibrand and Scott announced a bipartisan request for a Government Accountability Office investigation into how Washington funds and coordinates menopause research. The testimony put hard numbers on the gap: under 1% of federal women's-health research funding goes to menopause, 80% of OB-GYN residents say they feel unprepared to treat it, and menopause costs the US economy an estimated $26.6 billion a year. A hearing doesn't change your care by itself, but a GAO audit is how funding fights get their ammunition. Second, grounded coverage with my inference on the motive: creatine is being marketed hard to menopausal women this month - CNBC, Yahoo, and supplement outlets are all riding a small meta-analysis (7 trials, 608 women) of mostly muscle and bone outcomes. Plausible for muscle and bone if you also lift; unproven for hot flashes, mood, or brain fog. Same lesson as Tuesday's chasteberry trial: small, short studies tell you something works a little, not that it works for you. Third, grounded: the PMOS name keeps spreading - this week brought plain-language explainers from a major physician outlet and a large health system, which is exactly the shift Sunday's Part 4 update tracked from journals into patient-facing channels.

That's the cycle. Bring your doctor the papers, not just the headlines - and bring me your questions.

Dr. Herman Weiss

Medical Disclaimer

Use of this content does not create a doctor-patient relationship. Individual responses to treatments and lifestyle changes can vary, and only your healthcare provider can evaluate your specific circumstances. If you are experiencing a medical emergency, call your local emergency services immediately.

Chasteberry for menopause symptoms: a new trial says it works. Read the fine print with me.

Dr. Herman Weiss — Tue, 22 Sep 2026 06:49:37 GMT

Dr. Herman Weiss

Photo by Gabriele Carluccio on Unsplash

Sep 22, 2026

If you've spent any time in menopause spaces online, you've met chasteberry - Vitex agnus-castus, sold for centuries for "women's complaints" and now marketed hard as a natural, hormone-free answer to hot flashes, poor sleep, and mood swings. Until now, the honest answer to "does it work?" has been: we don't have good trials in postmenopausal women.

A new one just landed, and I want to walk you through it - because what it shows, and what it can't show, are equally useful to you.

The research. Published September 18 in Cureus, this was a randomized, double-blind, placebo-controlled trial of 60 postmenopausal women (aged 40-65) at a single hospital in Bengaluru, India. Half took a 300 mg Vitex extract capsule daily (standardized to 4.5 mg of the active compound agnuside), half took a matched placebo, for 60 days. Symptoms were tracked with validated instruments: the Blatt-Kupperman Index, MENQOL, and the Menopause Rating Scale. The trial was prospectively registered (CTRI, India).

What they found. The Vitex group improved on every measure, and the placebo group mostly didn't. Overall symptom severity (BKI) fell 31% on Vitex vs 7% on placebo. Vasomotor symptoms dropped 22% vs 4.5%. The Menopause Rating Scale fell 37% on Vitex while the placebo group barely moved. Stress markers and serum cortisol came down too, and no adverse effects or lab abnormalities were reported over the two months.

Now the fine print - and there's a lot of it. This trial was run by the manufacturer. The first author works for Ingex Botanicals, the company that makes the extract being tested. That doesn't automatically make the data wrong, but it means independent replication isn't a nice-to-have, it's the whole ballgame. The sample was 60 women at one center, followed for just 60 days - enough to detect a big short-term effect, not enough to know about smaller effects, rarer side effects, or durability. Menopause trials also have famously large placebo responses, and two months is precisely the window where expectation effects run highest. And Cureus is a low-barrier open-access journal; publication there means peer review happened, not that the findings are settled.

What you gain from this. If you're using chasteberry and feel better on it, this trial says you're not imagining a real short-term effect - and the safety record over 60 days was clean. If you're considering it, this is mildly encouraging evidence, the first properly randomized postmenopausal data we have, and it's reasonable to discuss with your doctor as a non-hormonal option while we wait for independent confirmation. What it is not: proof. One company-run, 60-person, 60-day trial does not overturn the decades-old rule that supplement claims should be believed after independent groups replicate them, not before. And no supplement has anything like the evidence base of hormone therapy for moderate-to-severe symptoms - if your symptoms are significantly affecting your life, that's the conversation to have first.

A note for our PMOS readers: this same herb is marketed heavily to you for cycle regulation and "hormone balance." The PCOS evidence for Vitex is even thinner than the menopause evidence - mostly small studies in PMS and cycle irregularity, nothing like this trial for PMOS itself. Same rule applies: interesting, watch for independent replication, don't let a supplement displace the metabolic fundamentals (insulin resistance screening, movement, sleep) that actually move your long-term risk. And if you're a woman with PMOS heading toward perimenopause, file this under "options to revisit when symptoms arrive with proper evidence," not "plan."

Citation: Reddy PA, Aluri S, Anzar CA, et al. Efficacy and Safety of Vitex Extract on Menopausal Symptoms and Quality of Life in Postmenopausal Women: A Randomized Placebo-Controlled Trial. Cureus. 2026;18(9):e116507. doi:10.7759/cureus.116507

Dr. Herman Weiss

Medical Disclaimer

The Name Is Starting to Move: PMOS, Four Months Later

Dr. Herman Weiss — Sun, 20 Sep 2026 12:16:22 GMT

Dr. Herman Weiss

Photo by Bradyn Trollip on Unsplash

Sep 20, 2026

When The Lancet published the global consensus renaming PCOS to PMOS in May, I said the name change was the starting gun, not the finish line, and this series would track whether the infrastructure underneath patient care actually moves. Part 1 covered what was real versus still on paper at three months. This past month produced the first unambiguous infrastructure move - and a few smaller ones worth noticing.

The big one: PMOS is now in the guidelines

NICE - the UK's National Institute for Health and Care Excellence, whose guidelines shape clinical practice well beyond Britain - has published a full draft guideline titled "Polyendocrine metabolic ovarian syndrome (previously known as polycystic ovary syndrome): assessment and management." Not a footnote acknowledging the rename: the term PMOS is used in the title and throughout the recommendations. The final version is expected December 9, 2026. [certain]

Two things about this matter more than the title. First, this is the stage of the 8-stage implementation roadmap that actually changes practice - guideline adoption is what turns a consensus paper into something a clinician is measured against. Second, look at what the guideline bothers to cover. Alongside cycles, androgens, and fertility, it has dedicated sections on metabolic health problems in adults, cardiovascular disease, diabetes screening, obstructive sleep apnea, endometrial cancer surveillance, depression and anxiety, and eating disorders - for everyone aged 10 and up, not just women trying to conceive. That is the entire argument of the reclassification, written into a national standard: this was never only a fertility condition, and the monitoring should never have stopped at the ovaries. [certain]

To be clear about what it isn't: it's still a draft (consultation closed in August), it's UK-only in force, and most of its recommendations adapt the 2023 Monash international guideline rather than introducing new evidence. A PDF in London doesn't change an appointment in Tel Aviv or Toledo tomorrow. But that's how these shifts actually happen - standards first, then training, then the defaults in the exam room. [likely]

The research establishment is saying it out loud

The same week, Cell Metabolism - one of the top metabolism journals, not a reproductive-medicine outlet - ran a commentary by Stener-Victorin, Zhao, Azziz, and Teede with a title that could be this series' thesis: "A new name, an old crisis: Metabolic dysfunction at the core of polyendocrine metabolic ovarian syndrome." These aren't peripheral voices: Teede led the international guideline, Azziz built much of the diagnostic framework the field has used for decades, and Stener-Victorin is one of the most-cited PCOS researchers alive. Their argument: the rename reframes "a profoundly misunderstood condition for which basic metabolic research remains critically underfunded and fragmented." [certain]

When the senior researchers who named the problem start publishing in metabolism journals rather than only in OB/GYN journals, that's the research infrastructure moving - grant categories, journal sections, and training programs follow where papers like this point. [likely]

And the clinicians are getting the memo

The American Journal of Obstetrics and Gynecology published its own primer in late August: "From PCOS to PMOS: What Obstetricians and Gynecologists Need to Know." Meanwhile, September being PCOS awareness month, mainstream outlets are running plain-language PMOS explainers. The vocabulary is spreading faster than I expected in Part 1 - though I still wouldn't bet on your own doctor saying "PMOS" this month, and that's fine. Vocabulary was never the metric; behavior is. [likely]

What's still on paper

Nothing has moved on ICD coding, billing, or EHR defaults - the stages that determine whether your chart, your insurance claim, and your screening reminders say PMOS or PCOS. Those are scheduled for the later stages of the transition plan, with full guideline integration still targeted for 2028. The honest scorecard, four months in: guidelines and research framing are moving ahead of schedule; the plumbing of daily care hasn't budged. [likely]

What I'd watch next: the NICE final publication on December 9 - the first complete national standard of care written under the PMOS name, and the template other countries' guidelines will be checked against. When it lands, I'll go through what it actually recommends for metabolic monitoring, because that's the part most likely to change what you're offered at your next visit.

Medical Disclaimer

Use of this content does not create a doctor–patient relationship. Individual responses to treatments and lifestyle changes can vary, and only your healthcare provider can evaluate your specific circumstances. If you are experiencing a medical emergency, call your local emergency services immediately.

The Pause Collective Science Review, Issue 3: September 14-18, 2026

Dr. Herman Weiss — Sun, 20 Sep 2026 10:49:00 GMT

Dr. Herman Weiss

Photo by Vitaly Gariev on Unsplash

Sep 20, 2026

Welcome back to the Pause Collective Science Review - the twice-weekly scan where I read the new research so you don't have to. This week's window (September 14-18) brought something new: for the first time, this review covers PMOS (the condition we used to call PCOS) alongside menopause, because these two audiences are one community. More and more, the science says the same thing.

1. Hormone therapy and liver cancer: 24 years of follow-up finally answers the question

What it studied. Researchers went back to the two big Women's Health Initiative hormone therapy trials - over 27,000 postmenopausal women randomized to estrogen-alone, estrogen-plus-progestin, or placebo - and asked a question no randomized trial had answered: does menopausal hormone therapy change the risk of primary liver cancer? They followed participants for nearly 24 years.

What it found. Reassuring, mostly. Seventy-four liver cancers occurred in total, with no significant difference between hormone therapy and placebo in either trial. Estrogen-plus-progestin did not increase liver cancer deaths. One subgroup signal deserves honesty rather than spin: among women aged 50-59, and among women who had used oral contraceptives in the past, the combination therapy group showed more liver cancers (10 vs 0 in the younger subgroup). The numbers are tiny, and the authors themselves call it a signal that "warrants further investigation," not a conclusion.

What it means. If you've seen liver-cancer scares attached to hormone therapy, this is the best evidence we have, and it's largely reassuring. The subgroup finding is exactly the kind of thing that should be studied more - not a reason to panic, and not a reason to dismiss.

Its limits. Liver cancer is rare, so even 24 years of WHI data gives us only 74 cases - the confidence intervals are wide, and the subgroup analyses are exploratory. These trials also used older oral formulations (conjugated equine estrogen with medroxyprogesterone acetate), not the transdermal estradiol and micronized progesterone most women use today.

One note for our readers with a PMOS history: the liver is ground zero for the metabolic side of PMOS - fatty liver disease is markedly more common in this group. Whether hormone therapy behaves any differently on an already metabolically stressed liver is genuinely unknown; this trial can't tell us. Worth raising with your doctor if it applies to you. (That's my inference from the population difference, not something this study measured.)

Citation: Pichardo MS, Aragaki AK, Manson JE, et al. Menopausal hormone therapy and primary liver cancer: long-term follow-up of the Women's Health Initiative randomized trials. British Journal of Cancer, 2026. https://www.nature.com/articles/s41416-026-03621-9

2. Not all estrogen receptors are the same - and that might explain a lot

What it studied. A systematic review and meta-analysis in BMC Women's Health pooled 13 randomized trials (1,115 menopausal women) of therapies that target specific estrogen receptor subtypes - ERalpha versus ERbeta - including SERMs, estetrol, and plant-derived "phyto-SERMs." The question: do receptor-selective treatments relieve hot flashes, mood symptoms, and bone loss differently?

What it found. Overall, ER-targeted therapies improved menopausal symptom burden, hot flashes, anxiety, and depressive symptoms compared with placebo. The exploratory subgroup pattern is the interesting part: ERbeta-preferring treatments looked more consistent for symptom relief, while ERalpha-predominant modulation showed possible skeletal benefits but limited symptom effect.

What it means. This is early evidence for an idea with real potential: matching the treatment to the receptor, not just "estrogen or no estrogen." If it holds up, it could eventually mean better-targeted options for women who can't or won't use conventional hormone therapy.

Its limits. The authors are admirably blunt: heterogeneity across studies was very high (I-squared over 90%), the depression result didn't survive sensitivity analysis, and the ERalpha conclusion rests on a single raloxifene trial. Their own verdict - "hypothesis-generating rather than clinically confirmatory" - is the right one. File this under "watch this space," not "change your prescription."

Citation: Wan M, Wei J, Hu J, et al. Targeting estrogen receptor subtypes in menopausal syndrome: differential effects on vasomotor symptoms, mood, and bone health - a systematic review and meta-analysis. BMC Women's Health, 2026. https://link.springer.com/article/10.1186/s12905-026-04849-6

3. What a mother's PMOS means for her children - and the answer is different for sons and daughters

What it studied. A prospective study from the Chinese University of Hong Kong, published in Fertility and Sterility, followed 71 women with PMOS and their 86 children (aged 15-25), comparing them with over 500 mothers without PMOS and their children. Offspring got detailed workups: body measurements, blood pressure, glucose, insulin, lipids, reproductive hormones.

What it found. The impact cascades a generation, but splits by sex. Daughters of PMOS mothers showed the reproductive signature early: 11% already met PMOS criteria (vs 0% of controls), menstrual irregularity ran at 58% vs 16%, and elevated androgens at 50% vs 26%. Sons showed the metabolic signature instead: hypertension and metabolic syndrome at roughly four times the control rate. A subtle finding with long shadows: the young people's blood glucose still looked normal, but markers of their insulin secretion were already lower - the pancreas compensating today, with less reserve for tomorrow.

What it means. PMOS is a family health condition, not only a women's health condition. If you have PMOS, your daughter's irregular cycles and your son's blood pressure deserve earlier attention than standard screening timelines suggest.

Its limits. One hundred and seventy-two offspring, one center, one population (Hong Kong Chinese families) - the effect sizes are large but the sample is small, and 15-25 is early; we don't yet know how these trajectories play out at 40 or 50. And association within families isn't proof of cause - shared genes, shared diet, and shared environment all travel together.

And here's where this community's two halves meet. Many women with PMOS are now approaching perimenopause carrying two decades of insulin resistance - the compounding risk I wrote about in my PMOS-to-perimenopause series. This study says their children may be starting adulthood with less metabolic reserve of their own. That's not a reason for fear; it's an argument for making metabolic screening a family habit rather than an individual afterthought.

Citation: Ng NYH, Chung JPW, Ma RCW, et al. Fertility and Sterility, 2026 (reported via CU Medicine, September 14, 2026). https://med.cuhk.edu.hk/press-releases/cuhk-reveals-health-risks-of-pmos-on-offspring-daughters-face-reproductive-issues-sons-face-much-higher-metabolic-risks

What social media is talking about this week

The first PMOS Awareness Month under the new name. September has always been PCOS Awareness Month; this is the first one since the May renaming, and mainstream outlets are running explainers under the new name (FOX 5 Atlanta, WESH, ELLE Singapore, among others). The vocabulary is genuinely spreading. What I like: most of these pieces lead with the metabolic story, which is the whole point of the new name. This is grounded - I read the coverage.

"I cut one food and lost 21kg." The Mirror ran a PMOS weight-loss testimonial this week, and social feeds are full of the genre: one food eliminated, transformation achieved. I'm glad for anyone feeling better, but there is no single-food cure in any PMOS guideline, and these stories quietly sell the idea that you failed if the same trick didn't work for you. The evidence supports overall dietary pattern, resistance training, sleep, and sometimes medication - boring, compound, and real. Grounded on the coverage; the genre characterization is my read of the current feeds.

Testosterone for women keeps surging. After Wednesday's FDA public meeting, coverage of testosterone prescribing for menopausal women - and the denials and delays women face getting it - ran across Reuters, CNN, and the Independent this week. I published a full breakdown of the FDA meeting here on Friday, so I won't repeat it; the social chatter matches what the data says about rising use, and the access complaints women are posting are consistent with the coverage.

The "PMOS gives you cancer" headlines. An EMJ piece this week highlights a large US insurance-database study: women with PMOS had 5.76 times the adjusted hazard of uterine cancer, with elevated hazards for ovarian, cervical, and breast cancers too. Two honest caveats before anyone spirals: the underlying study dates from May, not this week, and these are relative risks from an observational database - uterine cancer in young women is rare, so even a multiplied hazard stays a small absolute number, and association is not causation. The legitimate takeaway is the one the guidelines already give: if you have PMOS and long gaps between periods, that symptom deserves treatment, not just tolerance.

The estrogen patch shortage hasn't gone away. Coverage continued this week (ClearHealthCosts ran an explainer on the 17th). I flagged this in Issue 1; it remains a live problem, and if your pharmacy is out, ask about equivalent alternatives rather than going without - that's a conversation worth having now, not at the refill counter.

A quick note on process: two studies you may have seen covered elsewhere this week - the "menopause brain changes take a break" MRI work (van't Hof, Nature Communications) and the earlier-menopause/faster-brain-aging analysis - were both reviewed in Issue 1, so they're not re-annotated here. And the NICE draft guideline adopting the PMOS name gets its own dedicated post this weekend, not a rehash here.

Until Tuesday - read the science, keep the skepticism.

Dr. Herman Weiss

Medical Disclaimer

The FDA’s first-ever meeting on testosterone for women: what actually happened

Dr. Herman Weiss — Fri, 18 Sep 2026 05:37:05 GMT

For years, one question has come up in my clinic almost weekly: “What about testosterone?” And for years, the honest answer has been the same: the evidence supports it for one specific problem, no product is made for women, and the system makes it needlessly hard to get.

Yesterday, the FDA spent an entire day on exactly this. It’s worth paying attention.

What happened

On September 17, the FDA held its first-ever public workshop on testosterone use in menopausal women - a full day, in person and online, with regulators, researchers, clinicians, and patients in the room. The agency’s own framing: examine what’s known, map what’s missing, and chart a path toward testosterone products actually developed for women.

The timing tells the story. Testosterone prescriptions for US women have nearly tripled since 2023 (up 146%), yet there is no FDA-approved testosterone product for women, at any dose, for any condition. Doctors prescribe off-label: splitting gels designed for men, or turning to compounding pharmacies. Insurance rarely covers it, and pharmacies have started delaying or refusing these prescriptions. Meanwhile the UK, Australia, New Zealand, and South Africa all approve testosterone for women with low sexual desire.

The FDA’s public comment docket drew 744 submissions before the meeting, many from women describing what the treatment changed for them.

What was said

The headline moment came from the government’s own officials. The Assistant Secretary for Health, Admiral Brian Christine, opened by calling it unacceptable that American women have no approved testosterone product while Australian women do: “Something’s wrong with that,” he said, urging the FDA to “get this done.” The deputy director of the NIH’s child health and human development institute added that women deserve options “formulated and dosed specifically for them.” And FDA officials told manufacturers directly: we stand ready to review applications for female-specific products, and data from products already approved overseas can count, case by case.

The clinicians brought the balance. Dr. Rajita Patil, who directs UCLA’s comprehensive menopause program, was precise: the evidence today supports testosterone for one condition - hypoactive sexual desire disorder (HSDD), persistently low sexual desire that causes distress - and not for mood, cognition, or general well-being. She also warned against oral testosterone, which worsens cholesterol profiles. Others in the room pointed out the double standard: GLP-1 weight-loss drugs won multiple approvals without decades of safety data, while women’s sexual health waits.

The plain-English meaning

Testosterone in women declines steadily with age - by the late 40s, levels are roughly half of what they were in the early 20s. For some women that shows up as a loss of sexual desire that nothing else touches. For those women, low, female-appropriate doses are the one treatment with real evidence behind it, and it’s what international menopause guidelines endorse.

What’s broken isn’t the science - it’s the infrastructure. A woman needs a fraction of the male dose, but no product comes in that dose, so patients eyeball portions of a man’s gel packet. Pharmacists balk. Insurers say no. An approved female product fixes all of it: standard dosing, proper labeling, safety monitoring, and a fighting chance at coverage.

What you gain from this

Nothing changes at the pharmacy today. This was a workshop, not an approval. But the direction is unmistakable: the FDA is openly inviting manufacturers to bring female-specific products forward.
Your voice is literally on the record. The FDA’s public comment period stays open until October 19. If testosterone has mattered in your life, good or bad, the agency is asking to hear it: https://www.regulations.gov/commenton/FDA-2026-N-5479-0001
If you’re prescribed testosterone now, two questions worth asking your doctor: is the goal HSDD (the evidence-backed use), and is the dose a physiologic female dose rather than a scaled-down male one?

The honest caveats

The evidence supports testosterone for HSDD. Full stop. The energy, muscle, bone, mood, and general “wellness” claims filling social media do not have the data yet - the experts at the meeting said so explicitly.
Long-term safety beyond two years is unknown, especially for cardiovascular health and breast cancer. Testosterone converts to estrogen in the body, which is why it’s generally avoided in women with a history of breast cancer.
Excessive doses bring real side effects: acne, increased hair growth, and rarely voice deepening or hair loss that don’t reverse.
This is exactly why testosterone belongs with a physician who measures levels and follows you - not a wellness clinic selling pellets.

My take

I’ve watched women piece together testosterone therapy from products designed for someone else’s body, at doses they have to estimate, paid out of pocket, while four other developed countries simply approve it. Yesterday’s meeting doesn’t change a prescription pad today. But it’s the first time the FDA has said out loud that this gap is a problem to solve rather than a situation to tolerate. That’s how approvals start.

Dr. Herman Weiss

Medical Disclaimer

Your arteries start changing in your late 30s - not at menopause. Here’s the number to watch.

Dr. Herman Weiss — Wed, 16 Sep 2026 06:57:05 GMT

Ask most women when their heart risk starts climbing, and they’ll point to menopause - the moment estrogen drops and the arteries supposedly start to stiffen.

A new analysis from the Framingham Heart Study says that’s the wrong timeline.

The research. Published September 14 in Hypertension, an American Heart Association journal, the study followed 6,760 women across three health exams over 14 years (with 3,248 men for comparison). The researchers tracked pulse pressure - the gap between the top and bottom numbers of your blood pressure reading. That gap is one of the simplest windows into how stiff your largest artery, the aorta, has become.

What they found. In women, pulse pressure hits its low point and starts rising in the late 30s - about a decade earlier than in men (late 40s), and up to two decades before the final menstrual period. Here’s the part that surprised the investigators themselves: whether a woman reached menopause early, on time, or late made no difference to when that turn happened. The vascular shift simply isn’t pegged to menopause timing. After age 60, women’s average pulse pressure ends up higher than men’s - because women start with fewer elastic fibers in the aorta, the same aging process shows up harder.

To be clear, this doesn’t make menopause irrelevant. Dr. Samar El Khoudary, who chaired the AHA’s scientific statement on the menopause transition and wasn’t involved in the study, points out the trajectory may still accelerate in perimenopause. Her takeaway: don’t wait until menopause to think about cardiovascular health. By the final period, the changes may have been underway for years.

One number worth knowing: 60. A pulse pressure above 60 mm Hg - say, a reading of 130/70 - is considered wide. Wide pulse pressure is an independent risk factor for heart disease, dementia, and kidney disease, yet it isn’t part of standard blood pressure guidelines, and blood pressure with a wide gap tends to respond less well to the usual medications. Senior author Dr. Gary Mitchell’s advice: if a midlife woman is told her “borderline” 130 just needs watching, the follow-up question should be about the gap, not just the top number - and it should be tracked over time, not once.

What you gain from this. At your next appointment - or with your home cuff - do the subtraction: top number minus bottom number. If it’s consistently above 60, bring it up explicitly. Ask whether your readings are trending, and whether your treatment accounts for the gap. That’s a five-second calculation that can reframe a conversation your doctor might otherwise file under “borderline, keep an eye on it.”

Now the honest caveats. This is an observational study - it cannot prove cause and effect. Menopause timing was self-reported, not measured through hormone levels. And the Framingham participants were mostly of white European descent, so the findings may not apply equally to everyone. What it can tell us is that the turn happens early, it’s measurable, and it deserves attention in your 30s and 40s - not as an afterthought at 50.

Dr. Herman Weiss

Medical Disclaimer